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SUMMARY
The Support Vector Machine (SVM) classifier seeks to find the separating hy-
perplane wx = r that maximizes the margin distance 1/||w||22. It can be formalized as
an optimization problem that minimizes the hinge loss
∑
i(1− yif(xi))+ plus the L2-
norm of the weight vector. SVM is now a mainstay method of machine learning. The
goal of this dissertation work is to solve different biomedical data analysis problems
efficiently using extensions of SVM, in which we augment the standard SVM formula-
tion based on the application requirements. The biomedical applications we explore
in this thesis include: cancer diagnosis, biomarker discovery, and energy function
learning for protein structure prediction.
Ovarian cancer diagnosis is problematic because the disease is typically asymp-
tomatic especially at early stages of progression and/or recurrence. We investigate
a sample set consisting of 44 women diagnosed with serous papillary ovarian cancer
and 50 healthy women or women with benign conditions. We profile the relative
metabolite levels in the patient sera using a high throughput ambient ionization mass
spectrometry technique, Direct Analysis in Real Time (DART). We then reduce the
diagnostic classification on these metabolic profiles into a functional classification
problem and solve it with functional Support Vector Machine (fSVM) method. The
assay distinguished between the cancer and control groups with an unprecedented
99% accuracy (100% sensitivity, 98% specificity) under leave-one-out-cross-validation.
This approach has significant clinical potential as a cancer diagnostic tool.
High throughput technologies provide simultaneous evaluation of thousands of po-
tential biomarkers to distinguish different patient groups. In order to assist biomarker
discovery from these low sample size high dimensional cancer data, we first explore
x
a convex relaxation of the L0-SVM problem and solve it using mixed-integer pro-
gramming techniques. We further propose a more efficient L0-SVM approximation,
fractional norm SVM, by replacing the L2-penalty with Lq-penalty (q in (0,1)) in the
optimization formulation. We solve it through Difference of Convex functions (DC)
programming technique. Empirical studies on the synthetic data sets as well as the
real-world biomedical data sets support the effectiveness of our proposed L0-SVM
approximation methods over other commonly-used sparse SVM methods such as the
L1-SVM method.
A critical open problem in ab initio protein folding is protein energy function
design. We reduce the problem of learning energy function for ab initio folding to
a standard machine learning problem, learning-to-rank. Based on the application
requirements, we constrain the reduced ranking problem with non-negative weights
and develop two efficient algorithms for non-negativity constrained SVM optimiza-
tion. We conduct the empirical study on an energy data set for random conformations
of 171 proteins that falls into the ab initio folding class. We compare our approach
with the optimization approach used in protein structure prediction tool, TASSER.
Numerical results indicate that our approach was able to learn energy functions with
improved rank statistics (evaluated by pairwise agreement) as well as improved cor-




One of the main focuses in Bioinformatics is to develop efficient tools and methods
that are capable of analyzing and transforming the highly heterogeneous experimental
data into biological knowledge about the underlying mechanism. However, the ex-
ponential growth of the amount of biological data available present great challenges
in extraction useful information from these data. Therefore, machine learning tech-
niques, for example supervised learning methods, have been widely used to assist
researches in bioinformatics.
In this dissertation work, we extend support vector machine optimization, the cur-
rent mainstay of machine learning, to efficiently solve the reduced machine learning
problems from biomedical applications. To examplify our approach, we analyze prob-
lems from three different biological applications including cancer diagnosis, biomarker
discovery and protein energy function learning. We investigate the coupling of a high
throughput ambient ionization technique for mass spectrometry (MS) with machine
learning approaches for the metabolomic classification of sera from ovarian cancer
and control patients. We explore more aggressive feature selecting support vector
machine methods for biomarker discovery from high throughput cancer data sets.
We also study the problem of learning energy function for ab initio protein folding
through machine learning approaches.
Overall, we believe that these new support vector machine formulations and algo-
rithms could be the potential solutions for developing efficient machine learning tools
for researches in life science domains.
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1.1 Support Vector Machine Optimization
Given a dataset S = {xi, yi}mi=1 (xi ∈ Rn is the feature vector of ith data point and
yi ∈ {0, 1} is the corresponding label), for two-class classification problems, support
vector machine (SVM) learns the separating hyperplane wx = γ that maximizes the
margin distance 2||w||22
, where w is the weight vector and γ is the bias (see Figure 1).
Figure 1: Illustration of Max Margin Classification
Defining ξ as the slack variables, c > 0 as the error penalty parameter, diagonal
matrix Y ∈ Rm×m with Yii = yi, data matrix X = [x1, x2, · · · , xm]T , vector ek =
[1, 1, · · · , 1]T ∈ Rk, and identity matrix Ik ∈ Rk×k, we can formulate the linear SVM
learning problem into the following convex optimization problem.
min 1
2
|| w ||22 +c || ξ ||1
s.t.
Y (Xw − γem) + ξ ≥ em
ξ ≥ 0
(1)
Defining α ∈ Rm as the Lagrange multiplier and H as the kernel matrix with










The optimal weight vector is then computed as w =
∑m
i=1 yiαiyixi. α is usually a
sparse vector as only support vector xk ∈ SV has non zero αk values. The optimal
decision function for a data point x is defined as f(x) = w · x − γ. The prediction
label is +1 if f(x) > 0 and −1 otherwise.
Because of its theoretical guarantees and superior empirical performance, SVM
has become the interest of research in classification for decades and been successfully
applied to various scientific problems including biomedical applications.
1.2 Examples of Biological Applications
1.2.1 Ovarian Cancer Diagnosis
Despite decades of research and an annual investment in the U.S. of more than $2
billion on treatment, ovarian cancer remains the leading cause of deaths from gyne-
cological malignancies [16]. It is estimated that 21,880 women will be diagnosed with
and 13,850 women will die of cancer of the ovary in 2010 [79]. Due to the asymp-
tomatic nature of the disease, women are frequently undiagnosed until the disease is
late in its progression (stage III/IV) when the 5-year survival rate is only 15-20% [80].
The assay for CA125 is currently the only FDA-approved test for ovarian cancer de-
tection, however the overall positive predictive value of CA125 has been reported to
be less than 10% [83].
Most ovarian cancer biomarker discovery studies are based on the univariate or
multivariate anaysis of high throughput data focusing on qualitative or quantitative
changes (e.g. methylation, glycosylation) of large biopolymers (e.g. DNA, RNA,
glycans and proteins) [114]. In contrast, metabolic biomarker discovery approaches
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that focus on small molecules (below 1 kDa) have received significantly less attention.
We investigate the coupling of a high throughput ambient ionization technique
for mass spectrometry (MS), Direct Analysis in Real Time (DART), with machine
learning approaches for the metabolomic classification of sera from ovarian cancer
and control patients [126]. We reduce the task of classifying DART MS profiles into
a functional classification problem and solve it using functional SVM method. By
combining the DART-TOF MS with a customized fSVM classification algorithm, we
were able to distinguish sera from cancer patients and controls with 99% accuracy us-
ing the stringent leave-one-out cross-validation evaluation (100% sensitivity and 98%
specificity). We also estimate a clinically significant 12% PPV for our assay in this
sub-population, which is above the minimum value ( 10%) for a test to be considered
of clinical significance. We view this as a successful step towards the development of
an accurate new approach to the diagnosis of ovarian and other cancers.
1.2.2 Biomarker Discovery
Biomarker discovery, also referred as gene selection, metabolite panel selection, aims
to identify molecules (e.g., genes, metabolites) that are disease related. Biomarker
discovery allows to make the diagnostic process cheaper and targeted, and to narrow
down the number of biomarkers to better understand their biological significance. The
task is typically reduced into classification-driven feature selection and subsequent
biological validation.
High throughput technologies such as microarray, mass spectrometry, etc., pro-
vide simultaneous evaluation of thousands of potential biomarkers that distinguish
different patient groups. Cancer data sets generated by high throughput technolo-
gies are usually low sample size, consists of only a few hundreds patients. Our goal
is to develop more aggressive feature selection with similar or better accuracy than
previous techniques on these low-sample size high-dimensional cancer data sets.
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For this, we investigate two convex relaxations of the L0-SVM formulation and
propose efficient solution to the resulting optimization problems [43, 41]. Empirical
study on both simulations and real-world data sets support the effectiveness of the
fractional-norm SVM over other commonly-used sparse SVM methods. We believe
our approach is a promising feature selection method for biomarker discovery form
the low sample size high-dimensional data sets.
1.2.3 Protein Structure Prediction
Proteins are polymers assembled from 20 naturally occurring amino acids, which
fold to a unique, biologically active, three-dimensional conformation called the native
structure. Their functions are governed by their three-dimensional structures, which
in turn are fully determined by their amino acid sequences. Predicting the native
structure of a protein from its amino acid sequence, is one of the most important and
challenging scientific problems in contemporary biology and chemistry [36], [100].
The experimental determination of protein tertiary structure is a time consuming
and expensive process. Hence, computational methods play an essential role in the
native structure prediction of proteins.
There are three classes of computational based protein structure prediction ap-
proaches: homology modeling, threading and ab initio folding. For a query protein, if
none of its homologous sequences has an experimentally resolved structure, the only
remaining approach to predict its native structure is ab initio folding.
Ab initio folding attempts to find the native structure of a protein “from scratch”
(see Figure 12). A critical open problem in ab initio protein folding is protein energy
function design, which pertains to defining the energy of protein conformations in way
that makes folding most efficient and reliable. We address this issue as a weight opti-
mization problem and demonstrate a machine learning approach, learning to rank, to
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solve this problem. To maintain the physicality of the results, we constrain the prob-
lem with non-negative weights. We develop efficient algorithm to solve the resulting
non-negative RankingSVM problem [40]. We demonstrate an energy function which
maintains the correct ordering with respect to structure dissimilarity to the native
state more often, is more efficient and reliable for learning on large protein sets, and
is qualitatively superior to the current state-of-the-art energy function.
1.3 Thesis Organization
The rest of the thesis is organized as follows: In the next chapter, we investigate the
coupling of a high throughput ambient ionization technique for mass spectrometry
(MS) with functional support vector machine method for the metabolomic classifi-
cation of sera from ovarian cancer and control patients. In Chapter 3, we propose
two feature selecting support vector machine based convex relaxations of the L0-SVM
formulation to assist the task of biomarker discovery in low sample size and high di-
mensional cancer data sets. To better address the scalability issue on the low sample
size high dimensional cancer data sets, we further propose the fractional-norm SVM
problem and solve it through difference of convex programming technique. We reduce
the task of learning energy function for ab initio protein folding into a machine learn-
ing problem, ranking-via-classification. The reduction, optimization methods and the
results analysis are presented in Chapter 4. Conclusion and directions for future work
are discussed in Section 5.
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CHAPTER II
OVARIAN CANCER DETECTION FROM MASS
SPECTROMETRIC METABOLIC PROFILING
2.1 Introduction
Ovarian cancer (OC) is the most lethal of gynecological cancers and the 5th leading
cause of all cancer-related deaths among women [23] (see the statistics summary in
Figure 2). It is estimated that 21,880 women will be diagnosed with and 13,850
women will die of cancer of the ovary in 2010 [79]. While the 5-year survival rate
for women diagnosed with the disease early in its progression is greater than 90%,
the survival rate for patients diagnosed at later stages is only 20% [54]. The main
challenge with ovarian cancer is that it typically arises and progresses initially without
well-defined clinical symptoms [57]. Thus, successful diagnosis plays a central role in
deciding appropriate therapy and improving patient prognosis.
(a) Incident Rate (b) Death Rate
Figure 2: Top 10 Cancer Sites: 2003-2007, Female, United States
Although screening for specific biomarkers that are diagnostic of ovarian cancer
has been an active area of research since the early 1970’s [77], no effective diagnostic
tests are yet available. The assay for CA125 is currently the only FDA-approved test
for ovarian cancer detection but the overall predictive value of CA125 has been re-
ported to be less than 10% [83]. Most ovarian cancer biomarker discovery studies are
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based on the univariate or multivariate comparison of high throughput data focus-
ing on qualitative or quantitative changes (e.g. methylation, glycosylation) of large
biopolymers (e.g. DNA, RNA, glycans and proteins) [114]. In contrast, metabolic
biomarker discovery approaches that focus on small molecules (below 1 kDa) have
received significantly less attention, despite the fact that metabolic profiling of human
serum has long been touted as a promising technology for the early detection of many
diseases, including cancer [80]. In this trend, a few studies have reported individual
metabolites potentially useful for ovarian cancer detection, the most studied being
lysophosphatidic acid [7, 102, 117] and lipid associated sialic acid [84, 94, 95, 104, 110].
Since metabolites have vastly-differing chemical properties and occur in a wide
range of concentrations, mass spectrometry (MS) is a preferred method for broadband
metabolic profiling [33]. Although MS has been successfully applied in the develop-
ment of proteomic biomarker panels using surface-enhanced laser/desorption ioniza-
tion (SELDI) MS [83, 28, 71, 116] and matrix-assisted laser desorption/ionization
(MALDI) MS [92, 1], technologies such as liquid chromatography (LC) MS for the
effective analysis of the metabolome are still evolving as bioinformatic techniques for
the analysis of the resulting cancer data [107],[44].
We investigate the coupling of a high throughput ambient ionization technique for
mass spectrometry (MS) with machine learning approaches for the metabolomic clas-
sification of sera from ovarian cancer and control patients. This technique, known as
Direct Analysis in Real Time (DART) [27], is one of the members of the rapidly grow-
ing family of open-air (ambient) ionization methods for MS [49] that also includes
Desorption Electrospray Ionization (DESI) [81]. In this DART MS test, a stream of
excited metastables is used to desorb and chemically ionize a dried drop of derivatized
serum. A typical DART MS profile displays a multitude of signals corresponding to
metabolites rapidly desorbed and ionized in a time-dependent fashion (Figure 3(c.x)).
The classification of serum sample are further reduced into functional classification
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on these DART MS profiles, and solved with a customized functional Support Vector
Machine (fSVM) algorithm. The assay distinguished between the cancer and control
groups with 98.9% accuracy (100% sensitivity; 98-100% specificity) under leave-one-
out cross-validation evaluation.
The rest of this chapter is organized as follows: In the next section, we briefly
describe the workflow of the metabolomic investigation of patient blood serum samples
by DART-TOF MS as illustrated in Figure 3. In section 3, we present the reduced
functional classification problem on the DART MS profiles as well as the prediction
performance evaluation on the cancer data using functional SVM method. In Section
4, we discuss the biological significance of our data analysis results. The results
demonstrate the utility of this approach to derive panels of metabolic spectral features
that are potentially useful for the diagnosis of ovarian cancer.
2.2 DART MS Cancer Data Preparation
2.2.1 Sample Collection
Serum samples were obtained from the Ovarian Cancer Institute laboratory at Geor-
gia Tech after approval by the Institutional Review Board from Northside Hospital
and Georgia Institute of Technology (Atlanta, GA; Table 1). All donors were re-
quired to fast and to avoid medicine and alcohol for 12h prior to sampling, except for
certain allowable medications, for instance, diabetics were allowed insulin. Following
informed consent by donors, 5mL of whole blood were collected by venipuncture into
evacuated blood collection tubes that contained no anticoagulant (blood taken prior
to the administration of anaesthesia, immediately preceding surgery). Within one
hour of venipuncture, serum was collected and 200µL aliquots of each sample were
stored in 1.5mL micro-tubes at -80◦C until ready to use.
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(a) Serum sample preparation: i. protein precipitation, centrifugation and
separation of the metabolite containing supernatant followed by ii. evap-
oration of solvent to generate a metabolite-containing pellet. This pellet
is then subject to iii. derivatization to increase volatility of polar metabo-
lites. (b) Schematic of the DART-TOF mass spectrometer equipped with
a custom-built sample arm (iv. glow discharge compartment, v. gas
heater, vi. ionization region where sample-carrying capillary is placed),
vii. differentially-pumped atmospheric pressure interface to transport ions
towards the mass analyzer, viii. radiofrequency ion guide where ions are
collisionally cooled prior to entering the ix. orthogonal TOF mass ana-
lyzer. (c) Typical data are acquired in a time-resolved fashion (x. three-
dimensional contour plots of single runs corresponding to an ovarian cancer
patient (top), and a control (bottom)). The region of the time-resolved sig-
nal with best signal-to-noise ratio was averaged yielding xi. profile mass
spectra reflecting metabolic fingerprints. (d) Machine learning techniques
such as SVMs are used for building a multivariate classifier (xii. objects
in original variable space, xiii. objects in classifier space).
Figure 3: Diagram: Metabolomic Investigation of Serum Samples for Detection of
Ovarian Cancer
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Table 1: Patients analyzed in this study
Patient ID Ovarian Histopathology Stage/Grade Age at Surgery
242 papillary serous carcinoma IIIc/3 63
281 papillary serous carcinoma III/1 66
454 papillary serous carcinoma III/3 72
458 papillary serous carcinoma IIIc/3 59
472 papillary serous carcinoma IIIc/2-3 49
473 papillary serous carcinoma IIIc/3 48
491 papillary serous carcinoma I/ 74
495 papillary serous carcinoma IIIb/3 43
512 papillary serous carcinoma IIIb/2-3 59
517 papillary serous carcinoma Ia/3 59
526 papillary serous carcinoma IIIc/2-3 49
528 papillary serous carcinoma IIIc/3 66
529 papillary serous carcinoma IIIc 67
533 papillary serous carcinoma III/1 43
537 papillary serous carcinoma IIIa/2-3 64
542 papillary serous carcinoma IV/3 61
551 papillary serous carcinoma IIIc/IV/3 59
559 papillary serous carcinoma IV/3 49
588 papillary serous carcinoma IIIc/2-3 71
589 papillary serous carcinoma IIIc/IV/3 46
606 papillary serous carcinoma IIIa/3 54
617 papillary serous carcinoma IIIc/2-3 64
620 papillary serous carcinoma III/IV/3 62
632 papillary serous carcinoma IIIb/3 65
643 papillary serous carcinoma IIIb/2 59
644 papillary serous carcinoma IIIb/1-2 46
647 papillary serous carcinoma IIIb-c/3 68
651 papillary serous carcinoma IIIb-c/3 46
655 papillary serous carcinoma III/IV/3 75
659 papillary serous carcinoma IIIc/IV/3 78
678 papillary serous carcinoma IV/3 59
688 papillary serous carcinoma IIIc/3 59
694 papillary serous carcinoma IIIb/3 70
704 papillary serous carcinoma III/IV/3 75
717 papillary serous carcinoma IIIb/3 64
721 papillary serous carcinoma IIIc/1 58
756 papillary serous carcinoma IIIc/2 59
Continued on the following page. . .
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Table 1: Patients analyzed in this study
Patient ID Ovarian Histopathology Stage/Grade Age at Surgery
782 papillary serous carcinoma IIIc/3 59
787 papillary serous carcinoma IIIc/3 72
821 papillary serous carcinoma IIIc/1-2 58
831 papillary serous carcinoma IIIc/ 69
864 papillary serous carcinoma IIIc/3 60
876 papillary serous carcinoma IIa/1 63
5010 papillary serous carcinoma IIIc/1 59
440 within normal limits N/A 50
504 within normal limits N/A 48
523 serous cystadenoma N/A 32
534 within normal limits N/A 72
540 within normal limits N/A 59
541 within normal limits N/A 41
544 within normal limits N/A 49
552 within normal limits N/A 41
612 within normal limits N/A 48
614 within normal limits N/A 44
615 within normal limits N/A 42
623 simple cyst N/A 54
627 within normal limits N/A 59
636 within normal limits N/A 71
650 cystic corpus luteum N/A 47
677 within normal limits N/A 68
691 within normal limits N/A 70
693 simple cyst N/A 60
697 within normal limits N/A 51
698 functional cyst N/A 49
703 within normal limits N/A 42
719 fibrosis of tubal villi N/A 55
733 within normal limits N/A 37
736 within normal limits N/A 45
737 within normal limits N/A 41
740 functional cyst N/A 37
749 simple cyst/cystic follicles N/A 56
750 serous cystadenoma N/A 41
751 within normal limits N/A 60
752 within normal limits N/A 74
Continued on the following page. . .
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Table 1: Patients analyzed in this study
Patient ID Ovarian Histopathology Stage/Grade Age at Surgery
755 within normal limits N/A 75
757 within normal limits N/A 84
759 within normal limits N/A 52
763 hemorrhagic cyst N/A 45
765 within normal limits N/A 84
766 within normal limits N/A 36
783 within normal limits N/A 52
790 within normal limits N/A 39
796 within normal limits N/A 44
808 within normal limits N/A 35
828 simple cyst N/A 59
829 simple cyst N/A 33
838 within normal limits N/A 51
839 simple cyst N/A 79
842 fibrosis of tubal villi N/A 70
846 hemorrhagic corpus luteum N/A 51
848 within normal limits N/A 70
NHS1 healthy serum donor N/A 36
NHS4 healthy serum donor N/A 34
NHS10 healthy serum donor N/A 37
2.2.2 Sample Preparation
Prior to analysis, 200 µL of each serum sample were thawed on ice and mixed with
1 mL of freshly-prepared, chilled (-18◦C) and degassed 2:1 (v/v) acetone:isopropanol
mixture. The mixture was vortexed and placed in a freezer at -18◦C overnight to pre-
cipitate proteins followed by centrifugation at 13,000 g for 5 minutes. The supernatant
was transferred to a new centrifuge tube, and the solvent was evaporated in a speed
vacuum. The solid residue was re-dissolved in 25 µL of anhydrous pyridine (EMD
Chemicals, Gibbstown, NJ), and shaken for one hour at room temperature for com-
plete dissolution. Fifty µL of N-trimethylsilyl-N-methyltrifluoroacetamide (MSTFA,
Alfa Aesar, Ward Hill, MA) containing 0.1% trimethylchlorosilane (TMCS, Alfa Ae-
sar) were added to the sample in a N2-purged glove box. The mixture was then
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incubated at 50◦C in an inert N2 atmosphere for half an hour, resulting in TMS (tri-
trimethylsilane)-derivatization of amide, amine, carboxyl and hydroxyl groups. The
final derivatized mixture was subject to DART MS analysis.
2.2.3 DART-TOF MS
An in depth characterization of the analytical figures of merit of the DART MS
approach used here has been recently reported [127], and therefore, the method is only
briefly presented. Serum mass spectrometric analysis was performed using a DART
ion source (IonSense Inc., Saugus, MA) coupled to a JEOL AccuTOF orthogonal
time-of-flight (TOF) mass spectrometer (JEOL Inc., Japan). Prior to DART MS
analysis, 0.5 µL of derivatized serum solution was pipette-deposited onto the glass
end of the Dip-tip applicator (IonSense, Inc.) coupled to the sampling arm, a 1.2 min
data acquisition run started, and the sample allowed to air dry for 0.65 min. The
sampling arm was then rapidly switched so that the dried sample was exposed to the
ionizing zone of the DART ion source. After 0.9 min in the acquisition run (0.25 min
sampling time), the sample was removed, and a new Dip-tip placed on the sample
holder, while the remaining 0.3 minutes of the run were completed. Each sample was
run in triplicate.
The DART ion source was operated in positive ion mode with a helium gas flow
rate of 3.0 L min-1 heated to 200◦C. The glass tip-end was positioned 1.5 mm below
the mass spectrometer inlet. The discharge needle voltage of the DART source was
set to +3600 V, and the perforated, and grid electrode voltages set to +150 and +250
V, respectively. Accurate mass spectra were acquired in the range of m/z 60-1000
with a spectral recording interval of 1.0 s, and an RF ion guide peak voltage of 1200 V.
The settings for the TOF mass spectrometer were as follows: ring lens: +8 V, orifice
1: +40 V, orifice 2: +6 V, orifice 1 temperature: 80◦C, and detector voltage -2800 V.
Mass drift compensation was performed after analysis of each sample using a 0.20 mM
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polyethylene glycol 600 standard (PEG 600, Fluka Chemical Corp., Milwaukee, WI)
in methanol. The measured resolving power of the TOF MS was 6000 at full width
at half maximum, with observed mass accuracies in the range 2-20 ppm, depending
on signal-to-noise ratios (S/N) of the particular peak investigated. A repeatability of
4.1-4.5% was obtained for the total ion signal using a manual sampling arm.
2.2.4 Data Preprocessing
All profile mass spectra were obtained by time averaging of the total ion chronogram
between 0.73 and 0.76 minutes after each injection, that corresponds to the part
of the time-varying signal that is conducive to the maximum number of analytes
detected and identified with good sensitivity [127]. Following DART-TOF MS data
collection and mass drift compensation, the background spectrum was subtracted and
profile spectral data were exported in JEOL-DX format and converted to a comma-
separated format prior to importing in MATLAB 7.6.0 (R2008a, MathWorks). The
resulting data were normalized to a relative intensity scale and re-sampled to a total of
20,000 features between m/z 60 and 990 using the msresample function in the Matlab
Bioinformatics Toolbox. The three replicate DART spectra were then averaged. The
original dataset containing the DART-MS data can be downloaded [126].
2.3 Data Analysis
2.3.1 Functional Classification
In application domains such as chemometrics, it is well known that the shape of a
spectrum is sometimes more important than its actual mean value. Therefore, it is
beneficial to view the DART mass spectra as functions of m/z values (see Figure 4),
and perform functional classification. The goal of functional classification [10] is to
predict the label y of a functional data instance X given training data S = {Xi, yi}Mi=1,
where the input functional data instance Xi is a random variable that takes values in
an infinite dimensional Hilbert space H, the space of functions.
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(a) Normal Patient (b) Cancer Patient
Figure 4: Mass Spectrum as Function
In functional data analysis, each observation Xij of the data sample Xi arises
from a smooth curve xi(tj), t would be defined over time, space, wavelength, molecu-
lar weights and other continuums. Smoothness means that one or more of the curve’s
derivatives can be estimated. The observed data should provide enough information
to estimate the function underlies the curve and its properties. Often, n discretiza-
tion points have been chosen in t1, ..., tN ∈ R, and each functional data instance Xi is
described by a vector . Sometimes, the functional data instances are badly sampled
and the number and the location of discretization points are different between dif-
ferent instances. In practice, the functions that describe the input data instance will
represented by constructing an approximation (such as B-spline interpolation) based
on the observation values ((Xi1, · · · , XiN ∈ RN), and then sampling uniformly to the
reconstructed functional data ((xi(t1), · · · , xi(tN)) ∈ RN) [89].
2.3.1.1 Basis Expansion
A natural way to model the smooth shape of each curve observed over t (time, molec-






where Φ(t) = [φ1(t), · · · , φp(t)]T and ci represents the basis coefficients for the ith
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curve (corresponding to the ith instance). Given the functional building blocks, φk,
and dimension, n, the basis coefficients ci’s can be estimated by apply standard lin-
ear least squares, separately to each curve. This fitting process from observation
data Xi to function curve xi(t) is called as basis expansion (see Figure 5, black dots
represent the observation values, the green curve represents the underlying function
approximated through basis expansion).
(a) Example of Basis Functions (b) Example of Basis Expansion
Figure 5: Illustration of Basis Expansion
Common examples for basis functions include the Fourier, spline, and wavelet
bases. If the functional data are known to be non-periodic, spline bases generally yield
good results in practice [91]. We use B-Spline basis function in our experiments. The
spline function is a polynomial of fixed degree or order over any subintervals of the
observation interval, but the structure of the polynomial changes as one passes into
the next sub-interval by matching a certain number of derivatives between adjacent
sub-intervals. This class of basis functions are determined by:
• Number of sub-intervals (knots)
• Number of derivatives that are required to match at knot locations
• Degree or order of the polynomial segments (note that the order of a polynomial
is its degree plus 1)
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The number of basis functions in most spline setups is equal to the order of the
polynomial segments plus the number of knots. We use equal-sized segment with
degree 6 polynomials and second order derivative in our study, and curve flexibility
is achieved by controlling the number of knots (i.e., sub intervals).
2.3.1.2 Functional Support Vector Machine
It has been suggested recently that the classification performance on functional data
can be improved by designing SVMs specifically for functional classification [91, 111].
With the introduction of functional transformations and function kernels, functional
SVM method can be described as follows:
1. Apply functional transformation, projection PV n , on each instanceXi as PV N (Xi) =
xi = (xi1, · · · , xin) with Xi approximated by
∑N
k=1 xikΨk, where xik is a com-
plete orthonormal basis of the functional space H.
2. Build a standard SVM on the basis coefficients xi ∈ Rn for all i = 1, · · · ,M .
3. Apply projection PV n on the testing data point X, PV n(X) = c
4. Predict the label of the testing data point with the learned classifier with the
functional coefficients c ∈ Rk as input
This optimization procedure is equivalent to SVM optimization with a functional
kernel, Kn(xi, xj)
Kn(xi, xj) = K(PV n(Xi), PV n(Xj)) (4)
where PV n denotes the projection onto the n-dimensional subspace V
n ∈ H spanned
by {Ψk}k=1,··· ,n , and K denotes the standard linear SVM kernel.
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2.3.2 Feature Filtering
The analysis of variance (ANOVA) is one of the most commonly used filter-based
feature selection methods in bioinformatics. It helps to identify the features that
highlight differences between groups [60, 61]. Let the dataset S contain c classes
(groups), n data instances, and ni instances from each class ci; Xij(i = 1, · · · , c; j =
1, · · · , ni) be a random sample of size ni from a population with mean µi. ANOVA













2 is the total intra-class sum of squares, x̄i and x̄ are estimates of class and overall
sample means respectively; xij is an observation (sample) from class ci.
If the null hypothesis is rejected ([f > Fc−1,n−c(α)]) , the upper αth percentile
of the F-distribution with c − 1 and n − c degree of freedom), this implies that the
groups of data samples differ significantly.
2.3.3 Evaluation Framework
The prediction performance of the DART-TOF MS dataset was evaluated through
leave-one-out-cross-validation (LOOCV). Leave-one-out-cross-validation is generally
considered as a more rigorous evaluation approach due to its maximal usage of the
data for training [15, 14]. In this approach, at each 93-1 (n = 94 for our dataset) split
cross validation, the chosen feature selection method was applied only to the training
data, and then the prediction performance of the selected feature subset on the test
data was measured. In our previous study on metabolite ovarian cancer biomarkers
using LC-TOF (liquid chromagraphic - time of flight) MS technique, we show that
this evaluation framework (illustrated in Figure 6) can avoid the selection bias in the
prediction assessment [44].
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Figure 6: Evaluation Framework
SVM analysis of the DART mass spectra was performed using libSVM pack-
age [24]. fSVM analysis was performed using the FDA (functional data analysis)
package [88] and libSVM. Partial least squares discriminant analysis (PLSDA) [8, 115]
was performed using the PLS Toolbox (Eigenvector Research). We implemented the
ANOVA feature selection method in Matlab.
2.3.4 Results Discussion
As described in Section 2, this ovarian cancer data set consists of DART MS metabolic
profiles of 44 women diagnosed with serous papillary ovarian cancer (Stages I-IV) and
50 healthy women or women with benign conditions (e.g., serous, simple or follicular
cysts). We analyze the data set with the customized Support Vector Machine (SVM)
algorithm for classification of these metabolic profiles. The classification procedure
can be briefly described as follows:
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1. The data are collapsed along the desorption time dimension by using the av-
erage value within the time range of interest for all mass spectral m/z values
(”features”);
2. The resulting feature vector is smoothed using B-splines [89] to create the func-
tional representation;
3. The vector of spline coefficients is then utilized by the support vector ma-
chine [109].
Table 2: Prediction Performance (Accuracy %) on the DART MS Data Set
Feature Selection Features# Classifier SENS(%) SPEC(%) ACC(%)
One-way ANOVA
4390
fSVM 100 98 98.9
SVM 97.7 94 95.7
(α = 0.05) PLSDA 97.7 98 97.9
One-way ANOVA
2084
fSVM 97.7 100 98.9
SVM 97.7 98 97.9
(α = 0.01) PLSDA 93.2 92 92.6
every-7 sampling 2858
fSVM 100 98 98.9
SVM 95.5 92 93.6
PLSDA 93.2 90 91.5
For comparison purposes, we also evaluated the prediction performance of the data
set using conventional techniques such as PLSDA (partial least square discriminative
analysis) [8, 115] and SVM methods. In order to deal with the very large number
of features (20,000 m/z values per serum sample run), the data were subjected to
feature filtering before prediction performance evaluation. We compared the efficacy
of the classifiers through leave-one-out cross-validation (LOOCV) evaluation. During
LOOCV, each training set consisted of all patient samples except for one ”left out”
sample that is tested. In this way, each one of the patient samples is sequentially
treated as an unknown, classified by the model as ”cancer” or ”control” in a blind
fashion, and the accuracy of each classification evaluated. While validating models
21
by LOOCV, feature selection was performed independently on 94 different 93-1 split
validations (see Figure 6).
Figure 7: Visualization of a Functional SVM Classifier
As we can see from Table 2, all classification and feature selection methods showed
high accuracy (over 90%) owing to the inherent discriminative power of the data. For
example, combining with every-7-sampling feature filtering, only one 93-1 split vali-
dation of fSVM method resulted in a misclassification giving an overall accuracy of
99% (100% sensitivity and 98% specificity). The hyperplane of this 93-1 validation
is visualized in Figure 7. The x axis is the optimal weight vector of the fSVM model.
Red triangles with black edges correspond to ovarian cancer patients in the training
set, green circles with black edges to controls in the training set, larger red triangles
without borders are cancer patients in the test set, and the green circles without
borders are the control samples in the test set. As shown in the figure, the test-
ing data point in this validation, corresponding to control patient N749, which was
misclassified but very close to the separating hyperplane. According to the patient
information we collect, this patient has a very strong family history of ovarian cancer,
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this probably can explain why this particular patient was misclassified by our method.
Overall, the comparison study showed that fSVM method consistently outperforms
the conventional methods under different combination of feature selection methods.
The prediction performance of the conventional methods are more variational when
combined with different feature selection methods.
2.4 Bilogical Validation and Discussion
2.4.1 Metabolite Identification
Features in the fSVM model utilizing every-7 sub-sampling (1:7:20,000) were assigned
elemental formulae and tentatively matched to metabolites by finding the closest
mass spectral peak matching the model features in the [103, 714] m/z range. This
m/z range was chosen because it is fully covered by the TOF calibration function
thus providing the most reliable accurate masses. No attempt was made to match
fSVM model features outside this range. Accurate masses were searched against a
custom built database containing 2924 entries corresponding to elemental formulae
of endogenous human metabolites in the HMDB database [53]. Each entry was man-
ually expanded to take into account the mono, di and/or tri-trimethylsilane (TMS)
derivatives. Entries for families of compounds not reacting with the MSTFA/TMCS
reagent mixture were not expanded. Matching of database records to experimental
DART MS data was performed using the SearchFromList application part of the Mass
Spec Tools suite of programs (ChemSW, Fairfield, CA) using a tolerance of 10 mmu
to obtain candidate elemental formulae. If no matches were found, the next closest
match within 20 mmu was selected.
2.4.2 Pathway Enrichment Analysis and Metabolic Network Building
The MetaCore (GeneGO, St. Joseph, MI) software suite was used for metabolic net-
work analysis. One hundred fifty-three estimated elemental formulae [126] obtained
by DART MS accurate mass measurements of differentiating spectral features were
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Figure 8: Canonical Metabolic Pathways Relevant to the Identified Metabolites
assigned to 385 network objects by the metabolic network analysis software, of which
299 represented unique endogenous metabolites or xenobiotic compounds [126].
Metabolic compounds assigned to these elemental formulae by MetaCore were
mapped onto GeneGO canonical metabolic pathways that were ranked according to
their relevance to the input set using p-values calculated based on hypergeometric dis-
tribution. These differentiating compounds can be mapped onto 25 pathways with p-
values < 0.01. These 25 pathways are illustrated in Figure 8, and were ranked accord-
ing to their p-values (hypergeometric distribution). This suggests differences between
cancer and non-cancer groups in amine, amino acid, eicosanoid, and TTP (thymidine
triphosphate) metabolism. Suggested differences in metabolism of carbohydrates and
metabolism of androgens/estrogens have lower confidence since the relevance of cor-
responding pathways was determined from ambiguously identified metabolites (e.g.,
several different hexoses corresponding to elemental formula C6H12O6) and were not
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further examined.
2.4.3 Potential Biological Significance of Metabolic Changes in Ovarian
Cancer
A considerable proportion of the differentiating metabolites identified during the de-
velopment of our assay represent components of the histamine pathway [126]. Serum
histamine levels also have been reported to be altered in breast cancer [97]. Histamine
is known to serve as a receptor-dependent growth factor in some colon, gastric, breast
cancer and melanoma cell lines and to inhibit lymphocyte responsiveness via prolifera-
tion and activation of T lymphocyte suppressor cells [76]. In addition, the relationship
of histamine with the metabolism of nitric oxide, polyamines and angiogenesis is an
emerging area of interest in cancer biology [75]. The over-representation of members
of the histamine pathway in our metabolic panel suggests that these species also may
be of functional importance in ovarian cancer.
Other pathways over-represented in our dataset suggest that changes in the metabolism
of several amino acids (e.g., glycine) involved in the de novo synthesis of purine nu-
cleotides also are altered in ovarian cancer. Glycine, serine and sarcosine were all
tentatively identified as differentiating metabolites in our study and these metabolites
are components of over-represented canonical pathways of alanine, serine, cysteine,
threonine, and glycine metabolism [126]. Several amino acids from these pathways
previously have been identified in an earlier MS-based metabolic profile of ovarian
cancer tissues [32]. Sarcosine, the N-methyl derivative of glycine, is elevated in in-
vasive prostate cancer cell lines and in the tumors and urine of metastatic prostate
cancer patients [101]. Also consistent with our findings, levels of these amino acids
have all been previously reported to be elevated in colorectal [69], lung and breast [22]
cancer patient sera.
A number of other tentatively identified metabolites (e.g., dopamine, tyramine, 5-
hydroxykynurenamine and 1,2-dehydrosalsolinol) that are differentially expressed in
25
the sera of ovarian cancer relative to control patients are all products of decarboxyla-
tion of their precursor amino acids catalyzed by aromatic L-amino acid decarboxylase
(DDC). This enzyme and its metabolic products previously have been shown to be
elevated in neuroendocrine neoplastic tissues (carcinoid, small cell lung cancer; [22]).
We recently have reported that DDC is overexpressed in ovarian cancer [12]. Networks
built from our metabolic dataset using dopamine, tyramine, 5-hydroxykynurenamine
and 1,2-dehydrosalsolinol and their precursors [126] are consistent with the finding
that DDC (and its metabolic products) is (are) differentially expressed in ovarian
cancer.
2.4.4 The Utility of Metabolic Profiling as a Diagnostic Test for Ovarian
Cancer
Previous efforts to discover more accurate biomarkers of ovarian cancer using mass
spectrometry have generally focused on large biopolymers, such as proteins [86]. How-
ever, finding and validating biomarkers of this kind has been plagued by the fact
that the serum proteome is extremely complex, comprising ∼2×106 protein species
with a dynamic range spanning 10 orders of magnitude [4]. This inherent com-
plexity combined with current limitations in the proteomic analytical toolbox can
result in the convolution of biomarker variability with non-biological sources of vari-
ance. Comprised of ∼2,500 molecules with molecular weights < 1000 Da, the known
components of the serum metabolome can be readily distinguished from the serum
proteome and more thoroughly interrogated [82]. As biological studies using more
sensitive analytical tools with higher peak capacity improve our understanding of the
serum metabolome, the number of detected and identified metabolites is expected to
progressively increase, enriching the biological significance of discriminating spectral
features useful in diagnostics.
MS analysis of serum samples typically employs chromatographic separation. This
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step is usually time consuming and can result in increased costs and memory ef-
fects, which we believe was one of the confounding factors in our previous LC-MS
study [44]. Our DART method circumvents chromatographic separation, making
use of direct ionization without a matrix in a non-contact fashion. This decreases
cross-contamination between experiments, enabling a better detection of differences
between disease and control groups. Moreover, DART is able to ionize a broad range
of metabolites with varying polarities [26], allowing simultaneous interrogation of
multiple chemical species at minimal cost.
By combining the DART-TOF MS with a customized fSVM classification algo-
rithm, we were able to distinguish sera from cancer patients and controls with 99%
accuracy using the LOOCV test (100% sensitivity and 98% specificity). In this study,
the use of high resolution TOF MS was necessary for metabolite identification pur-
poses, but the spectral data were later down-sampled for machine learning purposes,
suggesting that approaches similar to the one presented here, but based on low reso-
lution MS data acquisition, may also be conducive to high discriminatory power.
There is general consensus among the ovarian cancer community that to be of
clinical significance, a diagnostic test for ovarian cancer must have a minimum positive
predictive value (PPV) of 10% [96]. Because the prevalence of ovarian cancer in the
general population is low ( 0.04%), the accuracy of any potential screening test to
be used in the general population must be extremely high ( 100%) [57]. While our
results indicate that our approach has great potential as a diagnostic tool of clinical
significance, more extensive testing will be required to define its use in screening
applications. Other, more immediate clinical applications of our assay may be in
those sub-populations of women where the prevalence of ovarian cancer is known to
be relatively high. For example, the estimated incidence of ovarian cancer in women
aged 20 and over with 2 first-degree relatives with ovarian cancer is 0.266% [18].
Using incidence to approximate prevalence [103], we estimate a clinically significant
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12% PPV for our assay in this sub-population assuming the LOOCV values of 100%
sensitivity, 98% specificity. Women 20 years of age and over who test positive for
BRCA1 or BRCA2 are reported to have an incidence of ovarian cancer as high as
0.683% [108]. For this group of women, our assay would have an estimated PPV of
26% – well above the minimum value ( 10%) for a test to be considered of clinical
significance.
The results presented here demonstrate the potential application of our method as
an ovarian cancer diagnostic of significant clinical value. In addition, if future studies
establish that metabolic profiles of different cancers and other diseases are sufficiently
distinct, our method may have the added advantage that it could be used to rapidly
and inexpensively test for multiple diseases from a small serum sample.
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CHAPTER III
BIOMARKER DISCOVERY FROM HIGH
THROUGHPUT CANCER DATA
3.1 Introduction
Biomarkers, a consensus definition of which is ”a characteristic that is objectively
measured and evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to a therapeutic intervention” [6, 112], are
crucial for successful disease diagnosis and treatment development.
High throughput technologies such as microarray, mass spectrometry, etc., pro-
vide simultaneous evaluation of thousands of potential biomarkers that distinguish
between different patient groups, e.g. normal versus cancer patients. For example,
Affymetrix U95Av2 microarray chip measures expression value of 12,558 genes per
patient; intensity values of 20,000 or more different m/z values can be extracted
from a DART-TOF mass spectrum of a patient. Because of the high experimental
cost, high throughput cancer data sets are usually low sample size, involving only
a few hundreds patients. Therefore, the high throughput cancer data are typically
low-sample-size and high-dimensional.
Biomarker discovery, also referred as gene selection, metabolite panel selection,
allows to make the diagnostic process cheaper and targeted, and to narrow down the
number of biomarkers to better understand their biological significance. The task is
typically reduced into classification-driven feature selection and subsequent biological
validation. An example of the biological validation process on the cancer biomarker
candidates is described in Section 2.4. Here, we focus on developing more aggressive
classification-driven feature selection methods that are suitable for these low-sample
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size high-dimensional cancer data sets.
A key difficulty for biomarker discovery such high-throughput cancer data is very
noisy, which can be caused by the intrinsic complexity of the biological processes
related to cancer, as well as experimental and technical imperfections. Another diffi-
culty arises from the low sample size and high dimensionality of the data. There is a
high risk of overfitting of standard feature selection method due to the small sample
size. Thus, there is an algorithmic need for developing feature selection for these high
throughput cancer data sets.
In this work, we address feature selection in the context of linear support vector
machine (SVM) learning [109]. For a two-class classification problem on a data set
S = {xi, yi}ni=1, where xi ∈ Rd is the feature vector of the ith data point, and











where L{f(x), y} = [1 − yf(x)]+ is the hinge loss, f(x) = wx − γ is the decision
function, w is the weight vector, γ is the bias term. Tuning parameter C > 0 controls
the trade-off between the goodness of data fit, as measured by the hinge loss, and the
complexity of model f , as measured by the L2-norm of the weights.
Existing approaches to feature selection for SVMs mainly fall into three categories:
filter-based methods, wrapper-based methods, and embedded methods. Filter-based
methods adopt feature ranking strategies disjoint from SVM training, such as t-
statistics, signal-to-noise ratio, etc. This type of feature selection methods usually
compute ranking score of each individual feature according to certain ranking criterion
and then select out the k best features (sorted by ranking scores). Although they
might be preferable because of computational efficiency and statistical robustness,
individual feature ranking is far from optimal in many cases [46].
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In real-world data sets, it’s very common that a feature that is useless by itself
can provide a significant prediction performance improvement when combined with
some others features. Therefore subset feature selection is desirable in spite of its NP-
hardness [3]. Wrapper-based methods assess the relative importance of feature subsets
based on their SVM hyperplane parameters or SVM performance on the training data.
Representative methods of this approach include recursive feature elimination [48],
and Weston’s R2W2 method [113], etc. Current wrapper methodologies usually adopt
greedy search strategies, such as forward selection and backward elimination, to avoid
exhaustive brute force feature subset search. However, these methods could still be
computational expensive.
Embedded methods augment the SVM formulation, and seek to learn the SVM
classifier as well as the optimal feature subset simultaneously in one optimization.
Significant examples of this approach include L1-norm SVM (L1-SVM) [13], Feature
Selection concaVe (FSV) [13, 67], etc. Embedded methods incorporate subset feature
selection as part of the SVM learning process, thus they might be more computational
efficient than wrapper-based feature selection methods.
In this work, we focus on deriving feature selecting support vector machine from
L0-norm SVM formulation. Unlike L1-norm SVM, which performs feature selection
as a by-product because of the resulting sparse solution, L0-norm SVM directly mini-
mizes on both hinge loss and cardinality of its weight vector. In the context of regres-
sion, where feature selection has been most throughly studied, it has been pointed out
that though L1 penalization yields sparse solutions, the estimates can be biased since
larger penalties are imposed on larger weight coefficients [34]. A recent comparison
study of least absolute shrinkage and selection operator (LASSO) regression [106] and
forward stepwise regression, which is a greedy surrogate of L0-regularization, further
indicated that L1-regularization never outperforms L0-regularization by more than a
constant factor, and in some cases, using an L1-norm penalty is much worse than an
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L0-norm penalty [72]. This comparison analysis also pointed out that “an approx-
imation solution to the right problem can be better than the exact solution to the
wrong problem” [72]. Our study follows this guideline.
The rest of this chapter is organized as follows: In the next section, we briefly
summarize several widely-used embedded feature selection methods. In section 3,
we describe the mixed-integer SVM problem and its convex relaxation formulated as
mixed-integer quadratic problems, and then present the comparison study on six real-
world data sets. To better address the scalability issue on the low sample size high
dimensional cancer data sets, we further propose the fractional-norm SVM problem
and solve it through difference of convex programming technique. The optimization
method and the results analysis on synthetic data sets and seven real-world data sets
are described in Section 4.
3.2 Related Work
3.2.1 L1-norm SVM
Bradley and Mangasarian (1998) [13] proposed the L1-norm SVM (L1-SVM) method,
which solves the following optimization problem.
min || w ||1 +c || ξ ||1
s.t.
Y (Xw − γem) + ξ ≥ em
ξ ≥ 0
(7)
L1-norm SVM method performs feature selection as a by-product of the resulting
sparse solution. Defining w = p− q, with p, q ≥ 0, Equation (7) is then equivalent to
the linear programming problem below,
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Y Xp− Y Xq − γY em + ξ ≥ em
p, q ≥ 0
ξ ≥ 0
. (8)
Several efficient algorithms are proposed for for L1-SVM optimization, such as
Fung and Mangasarian (2004) [37]; Zhu et al. (2004) [128]; Mangasarian (2007) [74],
etc. Because of its computational efficiency and the empirically sparse solutions,
L1-norm SVM method and its variants have been applied to various problems in
computation biology [44] and many other domains.
3.2.2 L0-norm SVM and Its Approximation Methods
Unlike L1-norm SVM method, L0-norm SVM directly minimizes on both hinge loss,∑
i[1−yi(wxi−γ)]+, and cardinality of its weight vector. However, optimizing the L0-
norm SVM is a NP-hard problem [3]. Previous work in this direction mainly includes
adopting smoothed approximations of the L0-norm, using adaptive scaling parameters
to control the sparsity. We select representative methods from each category for our
comparison study.
Weston et al. (2001) [113] introduced the idea of scaling variable, a feature is
removed if the corresponding scaling variable becomes zero during the optimization.
This method learns the optimal scaling variables and SVM classifier through mini-
mizing a generalization error bound, R2W 2,





s.t. eTnβ = 1, β ≥ 0
W 2(α, π) = min 1
2
αTY XΠXTY α− eTnα
s.t. αTy = 0, α ≥ 0
, (9)
where R2(β, π) minimizes the radius of the smallest sphere, centered at the origin,
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that contains all the data points; W 2(α, π) maximizes the margin distance of the
learned classifier, matrix Π = diag{π} and π ∈ {0, 1}d denote the scaling variables.
The above problem is relaxed to π ∈ Rd+ in the approximation algorithm. At each
iteration t, the algorithm first optimizes R2(β, π(t−1)) to get αt, and W 2(α, π(t−1)) to
obtain βt. Second, it updates π with gradient of R2(β(t), π)W 2(α(t), π). Third, it sets
the smallest nonzero πtk to zero, i.e. discards the corresponding feature. The above
procedure repeats until only d features left. We denote this method as R2W2.






j=1(1− exp−α|wj|). The resulting approximation of L0-SVM
is the Feature Selection concaVe (FSV) problem,





) + λeT (e− exp−α|w|)
s.t.
−Aw + eγ + e ≤ y
Bw − eγ + e ≤ z
y ≥ 0, z ≥ 0
, (10)
where A represents the data matrix of the positive training samples, and B is the
data matrix of the negative training samples.
Bradley and Mangasarian (1998) [13] solve Problem (10) using Successive Lin-
earization Algorithm (SLA), which iteratively update solution through optimizing
the linear programming problem below









−Aw + eγ + e ≤ y
Bw − eγ + e ≤ z
−v ≤ w ≤ v
y ≥ 0, z ≥ 0
. (11)
where (wt, γt, yt, zt) is the solution at the tth iteration. We denote this method as
FSV.
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Le Thi et al. (2008) [67] solved the FSV problem with DC programming. At each
iteration, they optimizes a linear programming problem based on DC decomposition,
J1(·) = G1(·)−H1(·). We denote this method as DC-FSV.







j=1 α | wj |
H1(w, γ, y, z) = λ
∑d
j=1(α | wj | −1 + exp−α|wj|)
. (12)
Fan and Li (2001) [34] proposed the smoothly clipped absolute deviation (SCAD)
penalty (Eqn. (13)) to approximate the L0-norm penalty,
pλ(|w|) =

λ|w| if |w| ≤ λ
− |w|
2−2aλ|w|−1
2(a−1) if λ < |w| ≤ aλ
(a+1)λ2
2
if |w| > aλ
. (13)
Zhang et al. (2005) [120] solved the SCAD-penalty regularized SVM problem











This is an iterative algorithm: at each iteration, it optimizes an unconstrained
quadratic programming problem derived from the quadratic approximation (Eqn. (15))
of the SCAD penalty,
[1− yi(b+ w · xi)]+ = 1−yi(b+w·xi)2 +
|yi−(b+w·xi)|
2






j − ŵ2j )
, (15)
where ŵj is the optimal solution from the previous iteration. We denote this method
as SCAD-SVM.
Liu et al. (2007) [73] proposed local quadratic approximation (LQA) algorithm
to optimize the Lq-SVM problem (Eqn. (20)). At each iteration, the algorithm opti-
mizes an unconstrained quadratic programming problem derived from the quadratic
approximation on the Lq-norm penalty,
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| wj |q≈| ŵj |q +
(| ŵj |q)
′
2 | ŵj |
(w2j − ŵ2j ) , (16)
where ŵj is the solution from the previous iteration. We denote this method as LQA.
3.3 Mixed-Integer SVM
In contrast to previous work, which either used a smoothed penalty function that ap-
proximates the L0-norm in the objective or used adaptive scale parameters, and then
solved through convex optimization techniques, we present the mixed-integer support
vector machine (MI-SVM) based on mix-integer relaxations on the L0-SVM formu-
lation, and then optimize the problem using mixed-integer nonlinear programming
(MINLP) techniques. Empirical comparison of our MI-SVM method with the stan-
dard SVM, L1-SVM, FSV, and Weston’s R2W2 feature selection methods, demon-
strates either sparser solutions with roughly identical classification performance, or
an increase in classification performance with similar or sparser representations.
3.3.1 Mixed-Integer Relaxations on L0-norm SVM
We consider the following L0-norm SVM formulation:
minw,γ,ξ || w ||0 +c || ξ ||1
s.t. Y (Xw − γem) + ξ ≥ em, ξ ≥ 0
(17)
Inspired by Gunluk and Linderroth’s work on perspective relaxation of indicator-
induced MINLP problems [45], we relax Problem (17) by introducing indicator vari-
able zj ∈ {0, 1}, zj = 0 ⇒ wj = 0 and zj = 1 ⇒ wj > 0; and the perspective
constraints w2j ≤ zjuj, where uj is the squared upper bound of the weight element
wj. These define a convex hull of w
2
j = zjuj, which is the equality we want to en-
force. The proposed mixed-integer SVM can then be formulated as the following










s.t. Y (Xw − γem) + ξ ≥ em, ξ ≥ 0
w2j − zjuj ≤ 0
z ∈ {0, 1}n, u ≥ 0, ξ ≥ 0
(18)
where vector z = [z1, · · · , zn]T , u = [u1, · · · , un]T , and constants a, c > 0 adjust
the trade-off between the cardinality of the weight vector and the hinge loss.
The above equation tries to minimize the L0-norm penalization
∑
j zj, the L2-
norm upper bound
∑
j uj, and the hinge loss
∑
i ξi. The first type of constraints
Y (Xw − γem) + ξ ≥ em, ξ ≥ 0 regulates the classification error for each training
instance. The second type of constraints w2j ≤ ujzj enforce that i) wj = 0 when
zj = 0, and ii) uj = w
2
j at optimal.
However, solving this problem directly with the existing MINLP tools such as
Bonmin [11] or MINLP [70] fails. The experiments of optimizing this problem over
even small datasets resulted in either infeasible states or unsatisfying solutions with all
indicator variable setting to zero. We believe that the failure of the nonlinear solvers
is due to a failure of constraint qualification on the conic constraints w2j ≤ zjuj.
For example, whenever zj = 0 during the tree-search or in the solution of continous
subproblems in Bonmin, the relaxation contains a constraint w2j ≤ 0, which violates
Slater’s constraint qualification [52]. While it is in principle straightforward to remedy
this situation by preprocessing the constraint w2j ≤ 0 and replacing it by wj = 0,
current nonlinear solvers do not perform this operation. The errors that we observe
from the nonlinear solvers are consistent with a failure of a constraint qualification.
To remedy this adverse situation, we thus relax the conic constraints w2j ≤ ujzj
into big-M constraints | wj |≤ Mzj, where M is a fixed large number (M was set to








s.t. Y (Xw − γem) + ξ ≥ em, ξ ≥ 0
| wj | −Mzj ≤ 0
z ∈ {0, 1}n, ξ ≥ 0
(19)
3.3.2 Results and Discussion
We compare the performance of the proposed MI-SVM method, with the standard
SVM, L1-SVM, FSV and Weston’s R2W2 feature selection methods on six real-world
biomedical data sets. We use the LibSVM package [24] for standard SVM opti-
mization and the L1-SVM code from [37, 74]. We implemente the FSV, and R2W2
methods in MATLAB. Due to numerical reasons, for FSV method, the elements of the




set to zero. We use CPLEX [55] to solve the mixed-integer SVM problem. Since the
CPLEX tool has the similar numerical issues, we can apply the same threshold rule as
the FSV method. We denote this approach as MI-SVM1. Furthermore, since we also
obtain the optimal indicator variable assignment after solving Eqn. (19), we would
apply standard SVM on the subset of the data that only contains the features with
non-zero indicator variables, and then obtain the final weight vector. We denoted
this approach as MI-SVM2.
3.3.2.1 Data Sets
We select four widely-used real world biomedical data sets from the UCI reposi-
tory [78] for our experiments. Ionosphere data set consists of 351 instances with
34 features. There are 225 radar returns termed “good” or showing some type of
structure in the ionosphere, and 126 radar returns termed “bad”; their signals pass
through the ionosphere. Wisconsin prognostic breast cancer (wpbc) data set consists
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of 198 instances with 32 numerical features representing follow-up data of the pa-
tients. Two of its variants are used. The first data set (denoted as wpbc24) includes
28 patients who had a cancer recurrence in less than 24 months and 127 patients who
didn’t have a cancer recurrence in less than 24 months. The second variant (denoted
as wpbc60) contains 41 patients with a cancer recurrence in less than 60 months, and
69 patients which cancer had not recurred in less than 60 months. SPECTF heart
data set: the training dataset consists of 80 instances with 44 features (40 instances
labeled with “1” and “0”, respectively); the testing dataset consists of 187 instances
with 172 instances labeled with “1” and 25 labeled with “0”.
We also use sub datasets of our metabolomic mass spectrometry cancer data
sets in our experiments. The OvarianCancer data set [44] consists of metabolomic
profiles of 37 ovarian cancer patients and 35 benign controls. Each metabolomic
profile contains intensity values of the same 592 features extracted from the LC/TOF
mass spectra of the patient serum. 360 of the 592 features are in the pos-ion-mode
and the remaining 232 features are in the neg-ion-mode. The DART data set [126]
consists of metabolomic profiles of 44 women diagnosed with serous papillary ovarian
cancer (stages I-IV) and 50 healthy women or women with benign conditions. The
metabolomic profiles are obtained using DART mass spectrometry technique. Each
metabolomic profile contains the intensity values of 20,000 features that are uniformly
resampled within m/z range [60, 990] based on the normalized raw DART-TOF mass
spectra. To reduce the curse of dimensionality, for each data set, we filter the features
according to t-statistics and select out the top 50 features for our study.
3.3.2.2 Parameter Tuning
We estimate the generalization ability of each method via 10-fold cross validation
(10-fold CV) on each data set, except for SPECTF data set as its training and
testing split are given. Note that we need to tune the parameter c of the standard
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SVM method and the RFE method, parameters δ, c of L1-SVM, parameter λ for FSV
method, and parameters a, c of the MI-SVM methods for the performance evaluation.
We employ the following parameter tuning procedure on each data set: for each
parameter setting, we perform a 10-fold CV, and the score for this parameter setting
is the averaged training accuracy over cross-validation. For SPECTF data set, we use
the training accuracy as its score. Then we select the parameter setting with the best
score (ties are broken by choosing the sparser solutions). The candidate parameter
values used in the experiments were
• c ∈ {2−7, · · · , 2−1, 1, 21, · · · , 27},
• δ ∈ {10−3, 10−2, 10−1, 1, 101, 102, 103},
• λ ∈ {0.05, 0.1, 0.15, · · · , 0.85, 0.9, 0.05},
• a ∈ {2−3, · · · , 2−1, 1, 21, · · · , 23}.
3.3.2.3 Result Analysis
Table 3: Feature Selection Performance (Number of Selected Features)
SVM R2W2 FSV L1-SVM MI-SVM1 MI-SVM2
OvarianCancer-50 50 49 17 24 17 13
DART-50 50 13 5 8 10 10
Ionosphere 33 30 30 30 31 31
wpbc24 32 27 5 24 19 24
wpbc60 32 22 19 25 21 16
SPECTF 44 21 34 28 12 12
on-average 40 27 18 23 18 18
Table 14 summarizes the feature selection performance, measured by the number
of features selected by each method. Table 4 describes the classification performance,
measured by testing accuracy of each classifier. Overall, the experiment results show
that MI-SVM methods are able to learn sparser representations with roughly identical
or increased classification performance. And MI-SVM2, the approach of applying
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Table 4: Classification Performance (Accuracy %)
SVM R2W2 FSV L1-SVM MI-SVM1 MI-SVM2
OvarianCancer-50 66.3 64.8 67.7 63.2 63.8 76.1
DART-50 78.8 91.4 96.7 95.7 95.7 95.7
Ionosphere 88.4 88.7 88.1 88.7 88.7 88.7
wpbc24 78.8 78.2 70.8 81.5 81.3 82.1
wpbc60 66.2 66.5 61.9 58.2 60.9 63.6
SPECTF 72.2 73.8 73.8 58.8 76.5 76.5
on-average 75.1 77.2 76.5 74.3 77.8 80.4
standard SVM onto the feature selection results of Eqn. (19) (features with non-
zeros indicator variables) had a higher prediction performance than MI-SVM1, the
approach of simply thresholding out the optimal weights of Eqn. (19) that having
relative small magnitude.
MI-SVM2 approach outperforms the other compared method with average testing
accuracy of 80.4% and average selected feature size of 18 over the six data sets. MI-
SVM1 and R2W2 methods had the second best testing accuracy (77.8% on average)
and MI-SVM1 were able to find sparser representation than R2W2 method. While L1-
SVM had the worst prediction performance (74.3% averaged testing accuracy) with
average of selected feature size of 23. In data sets such as wpbc24, SPECTF, Ovarian,
and DART, the testing accuracy increase significantly when using MI-SVM, which
indicates that some of the features in these datasets may be irrelevant to the disease.
In other data sets like Ionosphere, wpbc60, the prediction accuracy remains roughly
the same while sparsity increases, which suggests that these data sets may contain
redundant features. In both cases, our MI-SVM method consistently learns lower di-
mensional representations of the data sets with improved or comparable classification
performance. This demonstrates the effectiveness of MINLP techniques which have
not previous been widely used in machine learning.
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3.4 Fractional-norm SVM
Despite the improvement on prediction and feature selection performance, MI-SVM
optimization is very computationally expensive and the method is not applicable to
high-dimensional (or even medium feature size) data sets. To better handle the scal-
ability issue, we further propose the fractional-norm SVM problem, which achieve
sparsity by augmenting the SVM objective function with Lq-norm penalty term, for
q ∈ (0, 1). In this section, we describe our optimization solution to the fractional-
norm SVM problem with the Difference of Convex functions (DC) programming tech-
nique [85]. DC programming firstly decomposes a non-convex objective function into
the difference of two convex functions, and then solves the resulting problem through
a primal-dual approach. Under such a framework, we present an iterative algorithm
scheme for the fractional-norm SVM learning problem, which at each iteration solves
a reweighted L1-SVM problem. Therefore, we can reuse the existing efficient op-
timization methods for L1-SVM in our algorithm. We also give some theoretical
convergence guarantees about the algorithm. The empirical study with several pop-
ular sparse SVM methods indicates that the proposed DC programming approach
leads to better performance in both classification and feature selection, with good
computational efficiency, especially on low sample size high dimensional data sets.
3.4.1 Lq-norm Regularization
Lq-norm penalty is defined as Rq(w) =
∑
j | wj |q, for q > 0. Previous analysis on
the effect of Lq-norm regularization (also called as bridge penalty) in the context of
regression [66, 34, 129, 38], where feature selection has been most thoroughly studied,
indicated that:
• When q ≥ 1, the larger q is, the more penalties are imposed on coefficients with
| wj |> 1, and the less penalties are imposed on coefficients with | wj |< 1.
If q > 1, the Lq regularization does not threshold coefficients. If q = 1, small
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| wj |’s are tends to shrink to zero (i.e. achieving feature selection).
• When 0 < q < 1, the smaller q is, the more penalties are imposed on coeffi-
cients with | w |< 1, and the less penalties are imposed on coefficients with
| w |> 1. The Lq regularization may achieve better sparsity than the L1 reg-
ularization because larger penalty is imposed on small coefficients than the L1
regularization.
(a) q=0.1 (b) q=0.5 (c) q=1 (d) q=2
Figure 9: Feasible Region of Lq Regularization |w1|q + |w2|q ≤ 1
In the context of classification, especially SVM learning, the Lq-norm SVM prob-




L{f(xi), yi}+ Rq(w) . (20)
where hinge loss L(f(xi), yi) = [1− yif(xi)]+, decision function f(xi) = wxi − γ.
With q = 2, this is the standard SVM, which generally utilizes all the input
features in the learned decision function. With q = 1, this is the L1-SVM, which was
shown to perform reasonably well in many situations [13]. With q = 0, this is the
L0-SVM, which directly enforces sparsity with the cardinality of w, however, L0-SVM
optimization has been shown to be NP-hard [3].
Here, we consider the fractional-norm SVM (i.e., Lq-SVMs with q ∈ (0, 1)), due
to its promise as a middle ground between L0 (the most aggressively-sparse, but
intractable) and L1 (less sparse but much more tractable). For small values of q, it can
be seen as a quasi-smooth approximation of L0. Though promising, Lq regularization
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presents a much more difficult optimization problem than does L2 or L1, as the
objective function is non-convex and not differentiable at zero. In this work, we
develop practical algorithms for this little-explored approach to sparse SVMs [73].
3.4.2 Difference of Convex functions (DC) Programming
As mentioned previously, Lq-SVM has a non-convex objective function when q ∈
(0, 1). Therefore standard optimization routines may fail to find good minima of the
objective. We address this difficulty by adopting the technique of DC programming,
which seeks to decompose an objective function into convex parts, for which global
minima can be found, and then obtain a simpler non-convex function of these parts,
for which we are more likely to find good minima. In this section, we briefly review
DC programming technique and remarks on its convergence properties.
Given a non-convex objective function J and a DC decomposition of J ,
J(·) = G(·)−H(·) , (21)
the DC algorithm for minimizing J can be described in Table 5,
Table 5: General DC Algorithm Framework
Set an initial estimation w0 ∈ Dom(J) = {w ∈ Rd : J(w) <∞}
t = 0
Repeat
Select βt ∈ ∂H(wt) arbitrarily
Select wt+1 ∈ ∂G∗(βt) arbitrarily
t = t+ 1
Until convergence, e.g. minj(| wtj − wt−1j |) ≤ tol
where G,H : Rd → R are lower semi-continuous, proper convex functions, G∗(β) =
sup{wTβ −G(w)} is the conjugate function of G(w), and ∂H(w), ∂G∗(β) are subd-
ifferentials of H(w) and G∗(β), respectively.
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The subdifferentials of a lower semi-continous, proper convex function F (w), can
be defined as,
∂F (w) = {β ∈ Rd | F (w +4w) ≥ F (w) + (4w)Tβ , ∀4w ∈ Rd} . (22)
If F (w) is differentiable, then ∂F (w) = {OF (w)}. Furthermore, using standard
results on convex optimization [90] [Theorem 23.5], the subdifferentials can be com-
puted as in Eqn. (23). Therefore, a more analytical specification of the DC algorithm
framework can be obtained (see Table 6).
∂F (w) = arg maxβ∈Rd{wTβ − F ∗(β)}
∂F ∗(β) = arg maxw∈Rd{βTw − F (w)}
(23)
Table 6: DC Algorithm Framework Implementation
Set an initial estimation w0 ∈ Dom(J) = {w ∈ Rd : J(w) <∞}
t = 0
Repeat
Select βt ∈ ∂H(wt) arbitrarily
Select wt+1 ∈ arg minw∈Rd{G(w)− wTβt} arbitrarily
t = t+ 1
Until convergence, e.g. minj(| wtj − wt−1j |) ≤ tol
Pham Dinh and Le Thi (1998) proved that DC algorithm converges to a local
minimum, controlled by the initialization value w0 and the DC decomposition of the
objective function [85].
Theorem 1 [85] Given a nonconvex objective function J and a DC decomposition
J = G−H, if Dom(G) ⊂ Dom(H) and Dom(H∗) ⊂ Dom(G∗), then it holds for the
DC algorithm that
(i) Sequences {wt}t∈N (primal), {βt}t∈N (dual) are well defined.
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(ii) Objective value sequences {G(wt)−H(wt)}t∈N (primal), {H∗(βt)−G∗(βt)}t∈N
(dual) are monotonously decreasing, respectively.
(iii) If the minimum of J is finite and the sequence {wt}t∈N is bounded, every limit
point w̃ of the sequence is a critical point of J , that is the point satisfying the
local optimality condition of J . In particular, if J(wt+1) = J(wt), then wt is a
critical point of J in Eqn. (21).
Pham Dinh and Le Thi (2008) further extend the convergence analyses to objective
functions that are defined over convex sets [68]. Let Ω ⊂ Rd be a nonempty closed
convex set, then the optimization problem
min
w∈Ω
J(w) = G(w)−H(w) (24)
can be transformed into unconstrained DC programming problem
min J(w) = G̃(w)−H(w) , (25)
where G̃(w) = G(w) + ΓΩ(w) is a semi-continuous proper convex function with indi-
cator function ΓΩ(w) = 0, if w ∈ Ω and ΓΩ(w) = +∞ otherwise.
Moreover, DC programming can also be applied to functions defined on R2d+ ,
since the dual cone of R2d+ is still R
2d
+ , all the derivations of DC algorithm would
follow similarly [38]. Note that unlike convex concave procedure (CCCP) [119] and
surrogate maximization / minimization approaches [124], DC programming is capable
of optimizing non-convex objective functions that are non-smooth.
These convergence guarantees make the DC programming suitable for optimizing
the fractional-norm SVM, that is Lq-SVM with q ∈ (0, 1).
3.4.3 Solving the Fractional-norm SVM
The crucial point in applying the DC algorithm framework is to define a proper DC
composition of the objective function. We propose a DC decompositions for the
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fractional-norm SVM problem under local linear approximation. In this section, we
present the proposed DC decompositions, as well as the details of the DC iteration
of the nested algorithm.
3.4.3.1 DC Decomposition under Local Linear Approximation
If we approximate Lq∈(0,1)-penalty locally with L1-penalty, we can formulate a decom-










where decision function f(xi) =
∑
j wjxij − γ, L{f(xi, yi} = [1 − yif(xi)]+ is the
hinge loss functionG(w) is a L1-SVM type problem, and H(w) measures the difference
between the linear approximation and the Lq-penalty itself.
(a) q=0.1 (b) q=0.5 (c) q=0.9
Figure 10: Illustrations of the DC Decomposition of Fractional-norm SVM
If we define function h(wj) =| wj | − | wj |q, as per the graphical illustrations of
the decompositions (depicted in Figure 10), we can see that the functions h are not
convex on R. However, the restrictions on R+ are convex. Therefore, we rewrite the
fractional-norm SVM problem (Eqn. (20)) into










s.t. w+, w− ∈ Rd+, γ ∈ R
, (27)




j − w−j ) ∗ xij − γ.
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And we consider the following DC decomposition for Eqn. (27):















j )− (w+j + w−j )q]
. (28)
Therefore, the DC algorithm is still applicable to solve the fractional-norm SVM
problem given the convergence guarantees stated in Section 3.4.2.
3.4.3.2 DC Algorithm Specification for Fractional-norm SVM
According to the proposed DC decomposition (Eqn. (28)), the iterative optimization
scheme for Problem (27) can be specified as in Table 7.
Table 7: DC Algorithm for Fractional-norm SVM
Set an initial estimation w0 ∈ Dom(J)
t = 0
Repeat










where βtj = ∂h(w
t
j)
t = t+ 1
Until convergence of w





] , wj 6= 0 . (29)
To handle the computational issue when wtj ≈ 0, we can add a σ term to the de-
nominator [19, 93, 38]. Next, we determine ((wt+1)+, (wt+1)−) ∈ ∂G∗((βt)+, (βt)−).









[1− ((βtj)+ + (βtj)−)](w+j + w−j ) . (30)
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Problem 30 can be further reformulated to a linear programming problem,
min
w+,w−∈Rd+
C[en − Y X(w+ − w−) + γY en]+ + %T (w+ + w−) , (31)
where data matrix X = [x1, · · · , xn]T , label matrix Y = diag{ y1, · · · , yn}, en =
[1, · · · , 1]T ∈ Rn, %j = 1− |βtj| and % = [%1, · · · , %d]T ∈ Rd+.
Equation (31) is a reweighted L1-SVM problem. Recently, several efficient al-
gorithms have been proposed for optimizing L1-SVM [128, 37, 74]. Among all these
methods, we extend the work of [74], which is very competitive, to solve our reweighted
L1-SVM problem. As an observation from [74], we can show that the optimal solution
to the corresponding exterior penalty problem of Problem (31),
min −εeTnν + 12(|| (X
TY ν − %)+ ||2 + || (−XTY ν − %)+ ||2
+(eTnY ν)
2+ || (ν − Cen)+ ||2 + || (−ν)+ ||2)
, (32)
is also the solution of Problem (31), where ν ∈ Rn corresponds to the unconstrained
version of the Lagrange multipliers of Problem (31).
Problem (32) is an unconstrained optimization problem, and could be solved using
Newton method, which is a second order algorithm but enjoys fast convergence as









We initialize the DC optimization with the optimal solution of the corresponding
L1-SVM, i.e. w
0 ∈ arg minC
∑
i L{f(xi), yi} +
∑
j |wj|. And we terminate the DC
optimization whenever || wt+1 − wt ||∞≤ τ (τ = 10−3 for example) or the maximal
number of DC iterations is reached.
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3.4.4 Method Immplementation
In our experiments, all the methods are implemented in MATLAB. We use LibSVM
package [24] for the standard SVM optimization. And we use the L1-SVM optimiza-
tion code from Fung and Mangasarian (2004).
For fractional-norm SVM optimization, we initialize the DC optimization with the
solution of the corresponding L1-SVM problem (that is % = 1d). We modify the L1-
SVM code to solve the reweighted L1-SVM problem at each DC iteration. We adopt
an annealing strategy to adjust σ (used to avoid numerical issue when computing
subdifferentials of H) value. The algorithm starts from σ = 10−3, optimizes the
problem through DC algorithm until convergence, then scales down σ by a factor
of 10 and reruns the DC algorithm initialized with the optimization result of the
previous iteration. We stop the annealing procedure when σ = 10−10 or maximum
number of DC iterations is reached.
For R2W2 optimization [113], the W 2 term in the objective function is minimized
using LibSVM package and the R2 term is minimized using buildin MATLAB routine
quadprog. At each iteration, 10% of the remaining features with the smallest nonzero
scaling variables are removed. While for low-dimensional data sets such as wpbc24,
wpbc60, and the synthetic data sets, only the feature with the smallest nonzero scaling
variable is discarded at each R2W2 iteration.
For DC-FSV optimization [67], we solve the linear programming problem at each
DC iteration using buildin MATLAB routine (linprog). In the final output, the weight
elements with small relative magnitude, i.e.
|wj |
maxk(|wk|)
< 10−4, are set to zero. How-
ever, it’s easily to show that the linear programming problem arg minw{G1(w, γ, y, z)−
wT (∂H1(w))} could become unbounded during the DC optimization. Whenever this
situation occurs, we stop the optimization and use the result from the previous DC
iteration for thresholding and performance computation. In contrast, our fractional-
norm SVM method doesn’t have this computational issue since it guarantees % ≥ 0
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(see Eqn. (31)) during the DC optimization.
For SCAD-SVM optimization, following the experiments in [34, 120], we use the
standard SVM solution for initialization, and set the SCAD penalty parameter a = 3.7
and the thresholding value for removing features as 10−3.
For LQA optimization, we use the linear discrimination analysis solution for ini-
tialization [73]. At each LQA iteration, we discard features with small weight values,
| wj |< 10−3. Since its optimization formulation don’t guarantee a positive-definite
Hessian, we thus use Matlab routine pinv, which computes the Moore-Penrose pseu-
doinverse [9] of the hessian matrix, to get an approximation solution of the uncon-
strained quadratic programming problem at each LQA iteration.
3.4.4.1 Tuning Parameters
We employ the grid search procedure for parameter tuning. Note that for standard
SVM and R2W2 method, we need to tune parameter C > 0 for the performance
evaluation; for DC-FSV method, the tuning parameter is λ ∈ (0, 1); for SCAD-SVM
method, the tuning parameter is λ ∈ (0, 1]; for LQA method, the tuning parameters
are q ∈ (0, 2] and C > 0; for L1-SVM method, the tuning parameters are C, δ > 0;
and for our fractional-norm SVM method, the tuning parameters are C, δ > 0, and
q ∈ (0, 1). The candidate values of the parameters used for the experiments were
• C ∈ {2−7, · · · , 2−1, 1, 21, · · · , 27},
• δ ∈ {10−3, 10−2, 10−1, 1, 101, 102, 103},
• λDC−FSV ∈ {0.001, 0.002, · · · , 0.004, 0.05, 0.1, 0.2, · · · , 0.5},
• λSCAD−SVM ∈ {0.1, 0.2, · · · , 0.9, 1},
• qLQA ∈ {0.1, 0.2, · · · , 1.9, 2}
• qLqSVM ∈ {0.1, 0.2, · · · , 0.8, 0.9}.
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3.4.5 Simulation Study
In this simulation study, our objective was to assess the ability of the algorithms to
select a small number of target features in the presence of irrelevant and redundant
features. We generate the synthetic datasets following the example used in [113].
There are d = 202 features and only the first six dimensions are relevant. The first
three features x1, x2, x3 were drawn as xj = yN(j, 1) and the second three features
x4, x5, x6 were drawn as xj = N(0, 1) with a probability of 0.7, otherwise the first
three were drawn as xi = N(0, 1) and the second three as xj = yN(j − 3, 1). The
remaining features xj, j = 7, · · · , 202 are noise and independently generated from
N(0, 20). The probability of label y = 1 or −1 is equal. We consider various training
sample size: n = 60, 70, 80, 90, 100, 110, 120.
For each training sample size n, we repeat the following evaluation procedure
30 times for each method. We first generate a training data set of size n, and a
testing data set of size 500. Then we evaluate the method’s performance on the
training/testing datasets. The final classification and feature selection performance
of each method is computed as the average testing error and average number of
selected features over the 30 runs.
We employ a grid search procedure for choosing the right parameters for each
sample size. Candidate parameters for each method are listed in Section 3.4.4.1.
For each method under each parameter setting, we perform the above evaluation
procedure, and the score for this parameter setting is the averaged training error rate
over the 30 runs. Then we select the parameter setting with the best score (ties are
broken by choosing the sparser solutions).
We plot the trend of the classification performance of each method to the size of
the training sample size in Figure 11. x axis is the number of the training sample
size of the synthetic data sets. y axis is the average testing error rate of each method
over the 30 replicas. The SVM method performs poorly on these synthetic data
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Figure 11: Classification Performance on Synthetic Data Sets
sets, obtaining near random prediction performance (0.5 testing error rate) in most
cases. While testing error rates of the sparse SVM methods generally decreases as
the training sample size n increases. This suggests that feature selection is necessary
when many noise variables are present in the data set. The testing error rates of
the Lq-SVM and SCAD-SVM methods decrease prominently compared to those of
the LQA, DC-FSV and L1-SVM methods. R2W2 method has the best prediction
performance on synthetic data sets with training sample size n = 60, 70. The Lq-
SVM and SCAD-SVM methods surpass R2W2 method on synthetic data sets with
training sample size n = 80, 90, 100, 110, 120. Furthermore, our Lq-SVM methods
slightly performs better than SCAD-SVM method in all cases.
Table 8 lists the average number of features selected by each method over the 30
replicas. Since the SVM method is not designed to select variable, we didn’t include it
in this comparison. It is observed that our fractional-norm SVM method consistently
selects the smallest feature subsets in all cases. The DC-FSV, LQA method doesn’t
perform well on these synthetic data sets. In addition, we found that several sparse
SVM methods such as R2W2, SCAD-SVM and Lq-SVM methods are all able to
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include the relevant features into their feature selection results in most of the runs.
Our fractional-norm SVM method tends to be less affected by the irrelevant features
and thus achieves the sparsest feature selection results among these methods.
Table 8: Feature Selection Performance (Number of Selected Features) on Synthetic
Data Sets
R2W2 DC-FSV SCAD-SVM LQA L1-SVM Lq-SVM
n=60 12 49 53 17 27 11
n=70 14 57 50 14 31 12
n=80 17 63 45 16 32 12
n=90 18 70 40 25 32 12
n=100 19 74 38 27 31 12
n=110 21 78 39 27 31 12
n=120 24 83 44 28 32 13
3.4.6 Empirical Study on Real World Data Sets
We further conduct a comparison study on seven real-world data sets (see Table 9)
through 10-fold cross validation. For each data set, we permuted the order of the
data samples before 10-fold partition, and we partitioned the data samples such that
each fold has the same number of negative data samples and the same number of
positive data samples. The performance of each method is measured in terms of
averaged testing error rate and sparsity of the 10-fold cross validation under their
respective optimal parameter settings, and its average computation time of a 10-fold
cross-validation averaged over all the parameter settings. In which, sparsity is defined
as the ratio of size of selected feature subset and the total feature size.
We employ the following grid search procedure for choosing the right parameter
setting for each data set. For each possible parameter setting (see Section 3.4.4.1), we
perform the 10-fold cross-validation, and the score for this parameter setting is the
averaged training error rate over the 10-fold cross-validation. The parameter setting
with the best score (ties are broken by choosing the sparser solutions) is chosen for
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the final comparison.
Table 9: Statistics of the Data Sets
Data sets Feature Size (d) Sample Size (n) Class Distribution (n+/n−)
arcene 10000 200 88 / 112
ColonCancer 2000 62 22 / 40
OvarianCancer 592 72 35 / 37
PancreaticCancer 6771 181 80 / 101
ProstateCancer 12600 102 52 / 50
wbpc24 32 155 28 / 127
wbpc60 32 110 41 / 69
3.4.6.1 Data Set Description
We use four public microarray gene expression data sets and three mass spectrometry
data sets in the comparison study (see Table 9).
• arcene data set is from NIPS 2003 feature selection challenge [47]. The task
of Arcene is to distinguish cancer (ovarian or prostate cancer) versus normal
(healthy or control) patterns from mass spectrometric data. Note that in our
experiments, we combine the training data (100 cases) and validation data (100
cases) of the arcene data set.
• Colon cancer data set [2] consists of 62 tissue samples (22 normal and 40 colon
cancer) probed by oligonucleotide arrays. The data set contains expression
values of the 2000 genes with highest minimal intensity across the 62 tissues.
Some genes are non-human genes.
• The ovarian cancer data set [44] consists of mass spectrometry metabolomic pro-
files of 37 ovarian cancer patients and 35 benign controls. Each metabolomic
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profile contains intensity values of the same 592 multimode features (360 in pos-
ion-mode and 232 in neg-ion-mode) extracted from the liquid chromatography/time-
of-flight mass spectra of the patient serum.
• Hingorani et al. (2003) [51] explored the ability of the low molecular weight in-
formation in discriminating premalignant pancreatic cancer compared to control
animals. A data set consists of 80 PANIN (pancreatic intraepithelial neoplasias)
and 101 control murine sera samples were provided from their website.
• The prostate cancer data set [98] consists of 52 prostate tumors and 50 nontu-
mor prostate samples. The gene expressions were measured using high-density
oligonucleotide arrays with probes for 12600 human genes and ESTs.
• The wpbc24 and wpbc60 data sets are build on the the Wisconsin prognostic
breast cancer patient follow up data set (wpbc) [78], including the 30 nuclear
features plus diameters of excised tumor and number of positive lymph nodes.
For wpbc24 data set, the two classes were patients with recurrence before 24
months (28 cases), and patients with recurrence after 24 months (127 cases).
For wpbc60 data set, the two classes were patients with recurrence before/after
60 months (41 cases and 69 cases, respectively).
3.4.6.2 Performance Evaluation
The first set of experiments evaluated the seven methods on the ColonCancer, Ovari-
anCancer, wpbc24, wpbc60 data sets. Table 10,11 depicts their performance over the
10-fold cross validation under the optimal parameter setting, respectively. The val-
ues in the parentheses are the standard errors over the 10-fold cross validation of the
corresponding mean values.
Comparing to L1-SVM method, many of the L0-SVM approximation methods
(DC-FSV, SCAD-SVM and our fractional-norm SVM methods) were able to obtain
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Table 10: Classification Performance (Accuracy %)
Datasets SVM R2W2 DC-FSV SCAD-SVM LQA L1-SVM Lq-SVM
ColonCancer 91 82.6 81.9 77.4 77.4 75.5 82.1
( 4.6 ) ( 11.1 ) ( 14.6 ) ( 11.5 ) ( 11.5 ) ( 14.5 ) ( 14.1 )
OvarianCancer 78.7 48.4 73.0 70.4 58.8 72.9 76.1
( 14 ) ( 18.2 ) ( 20.8 ) ( 19.9 ) ( 11.3 ) ( 20.7 ) ( 17.8 )
wbpc24 78.8 80.1 65.4 80.1 80.8 78.8 81.3
( 5 ) ( 4.4 ) ( 12.7 ) ( 4.4 ) ( 4.7 ) ( 7.6 ) ( 5.4 )
wbpc60 66.2 65.4 63.5 67.2 68.0 61.0 68.0
( 8 ) ( 8.5 ) ( 9.7 ) ( 10.8 ) ( 10.0 ) ( 10.9 ) ( 10.3 )
on-average 78.7 69.1 71.0 73.8 71.2 72.0 76.9
Table 11: Feature Selection Performance (Sparsity)
Datasets R2W2 DC-FSV SCAD-SVM LQA L1-SVM Lq-SVM
ColonCancer 0.005 0.003 0.003 0.005 0.011 0.005
( 0.0007 ) ( 0.0015 ) ( 0.0008 ) ( 0.0009 ) ( 0.0016 ) ( 0.0007 )
OvarianCancer 0.068 0.063 0.053 0.026 0.071 0.068
( 0.016 ) ( 0.005 ) ( 0.005 ) ( 0.086 ) ( 0.005 ) ( 0.006 )
wbpc24 0.869 0.481 0.091 0.791 0.781 0.119
( 0.0 ) ( 0.0 ) ( 0.1 ) ( 0.1 ) ( 0.033 ) ( 0.038 )
wbpc60 0.691 0.491 0.184 0.228 0.788 0.306
( 0.16 ) ( 0.044 ) ( 0.083 ) ( 0.026 ) ( 0.041 ) ( 0.041 )
on-average 0.408 0.259 0.083 0.263 0.413 0.125
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sparser representation of these data sets while archive improved or at least similar pre-
diction performance. This observation support the analysis that L0-SVM optimiza-
tion is able to achieve more aggressive feature selection than L1-SVM optimization.
Overall, our fractional-norm SVM method shows robust performance: consistently
achieving improved prediction performance as well as sparse solutions with decent
runtime.
Table 12: CPU Runtime (Seconds) of a 10-fold Cross-Validation
Datasets SVM R2W2 DC-FSV SCAD-SVM LQA L1-SVM Lq-SVM
ColonCancer 1 2014 207 867 921 4 21
OvarianCancer 1 9572 220 100 669 2 22
wbpc24 1 1583 15 36 5 2 14
wbpc60 1 1524 6 30 8 1 7
on-average 1 3673 112 258 401 2 16
We can see from Table 12 that Mangasarian’s L1-SVM optimization algorithm is
very efficient although it is a second-order algorithm. The computation time of our
fractional-norm SVM method is roughly bounded by that of the L1-SVM algorithm
times the maximum number of DC iterations. R2W2 method requires the largest com-
putational time. There are three main reasons: i) The number of R2W2 iterations
depends on the number of features. ii) Each R2W2 iteration includes optimization
of two quadratic programming problems minR2, minW2, and a gradient descent
update. iii) The optimization time of the two quadratic programming problems in-
creases dramatically when the remaining feature size becomes too small (< 30). Thus
we terminate R2W2 procedure if runtime of current iteration exceeds 100 seconds.
We also notice that the computation time of DC-FSV, SCAD-SVM, and LQA
methods on OvarianCancer and ColonCancer data sets (feature size 592, 2000, re-
spectively) increases a lot comparing to their computation time on wpbc24 and wpbc60
data sets (feature size 32). This fact suggests that these methods might not be scal-
able to high dimensional datasets. The same conclusion can also be derived from the
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analysis on their optimization formulation. At each DC iteration, DC-FSV algorithm
optimizes a linear programming problem of O(n) + O(d) variables and O(n) + O(d)
constraints. At each optimization iteration, SCAD-SVM and LQA methods, need to
compute the inverse or pseudo-inverse of its hessian matrix, which is a d× d matrix.
Therefore, if thresholding on the initial solution (e.g. solution of standard SVM)
wasn’t able to reduce the feature size substantially, the three methods could fail on
high-dimensional data sets .
Table 13: Classification Performance (Accuracy) on High Dimensional Data Sets
Datasets SVM R2W2 L1-SVM Lq-SVM
arcene 91 64 58 70
( 4.6 ) ( 15.1 ) ( 12.3 ) ( 12.7 )
PancreaticCancer 70.2 61.3 53.6 67.4
( 10.4 ) ( 12.4 ) ( 9.2 ) ( 11.4 )
ProstateCancer 91.2 88.4 85.2 91.2
( 5.7 ) ( 8.9 ) ( 12.8 ) ( 5.7 )
on-average 84.1 71.2 65.6 76.2
In the second set of experiments, we compare the methods on the three high-
dimensional data sets in terms of feature selection performance (Table 13), prediction
performance (Table 14), and computational cost (Table 15). DC-FSV, SCAD-SVM,
and LQA methods are not included in this set of experiments, because we keep
getting out-of-memory error messages when applying these methods onto these high-
dimensional data sets. Overall, the comparison showed that, our fractional-norm
SVM method is able to achieve sparse solutions, comparable to those of the R2W2
method, with better prediction performance with reasonable running time.
We can see from Table 15 that SVM learning time increases with feature dimen-
sions as well as sample size. R2W2 method still require the largest computational
time. We apply the same termination rule for R2W2 method, the method will be
terminated if the running time of current iteration exceeds 100 seconds. For L1-SVM
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Table 14: Feature Selection Performance (Sparsity) on High Dimensional Data Sets
Datasets R2W2 L1-SVM Lq-SVM
arcene 0.003 0.004 0.003
( 0.0005 ) ( 0.003 ) ( 0.0002 )
PancreaticCancer 0.005 0.007 0.007
( 0.0006 ) ( 0.0003 ) ( 0.0005 )
ProstateCancer 0.001 0.002 0.001
( 0.0002 ) ( 0.0002 ) ( 0.0002 )
on-average 0.003 0.004 0.004
method, the complexity at each Newton iteration is of O(n2d) +O(n3), thus we also
see an increase of computational time on these high-dimensional data sets. But it is
still very efficient comparing to that of the R2W2 method. The computation time
of our fractional-norm SVM method is still roughly bounded by that of the L1-SVM
algorithm times the maximum number of DC iterations.
Table 15: CPU Runtime (Seconds) of a 10-fold Cross-Validation
Datasets SVM R2W2 L1-SVM Lq-SVM
arcene 144 6075 81 875
PancreaticCancer 25 6769 98 592
ProstateCancer 10 1192 71 456
on-average 60 4679 58 641
In summary, we observed that on data sets such as wpbc24, wpbc60 and Prostate-
Cancer, the prediction performance of feature-selecting SVM methods such as fractional-
norm SVM, SCAD-SVM are better than that of the standard SVM method, indi-
cating that many features in these data sets may be irrelevant. In data sets like
OvarianCancer, ColonCancer and PancreaticCancer, the prediction error rate re-
mains roughly the same after applying feature-selecting SVM methods such as R2W2
or fractional-norm SVM, suggesting that these data sets may contain redundant fea-
tures. In arcene data set, none of the sparse SVM methods beats the standard SVM
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method in prediction accuracy. This is probably because arcene data set contains
both ovarian cancer or prostate cancer patients, and these two types of cancer should
correspond to different subset of biomarker candidates. The random splitting in the
10-fold cross validation experiment probably did not generate balanced partitions
of ovarian/prostate cancer patients. The different ovarian/prostate cancer patient
distribution in the training/testing partition thus resulted in bad performance for
these sparse SVM classifiers. In all three cases, our fractional-norm SVM method can
robustly realize a proper trade-off between prediction accuracy and the number of se-
lected features within decent runtime. Moreover, the sparse decision functions learned
with our method are generally more predictive than those produced by L1-SVM or
other L0-SVM approximation methods.
3.5 Discussion
In order to assist high throughput biomarker discovery, we investigate feature se-
lecting support vector machine based on convex relaxations of L0-SVM formulation.
We propose the mixed-integer support vector machine and explore the mixed-integer
nonlinear programming techniques which have not previous been widely used in ma-
chine learning. We further propose an practical solution to the fractional-norm SVM
problem, an more efficient L0-SVM approximation, using the difference of convex
functions programming technique. The empirical study support the effectiveness of
the fractional-norm SVM over other commonly-used sparse SVM methods.
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CHAPTER IV
LEARNING PROTEIN FOLDING ENERGY FUNCTION
4.1 Introduction
Proteins are polymers assembled from 20 naturally occurring amino acids, which
fold to a unique, biologically active, three-dimensional conformation called the native
structure. Their functions are governed by their three-dimensional structures, which
in turn are fully determined by their amino acid sequences. Predicting the native
structure of a protein from its amino acid sequence, is one of the most important and
challenging scientific problems in contemporary biology and chemistry [36], [100].
The capability to reliably make such predictions would allow biochemists to design
drugs more efficiently, understand various biological processes in details, and answer
many fundamental questions about biological systems, diseases, immune response,
and more.
The experimental determination of protein tertiary structure is a time consuming
and expensive process. Hence, computational methods play an essential role in the
native structure prediction of proteins. There are three classes of computational
based protein structure prediction approaches: homology modeling, threading and
ab initio folding. Both homology modeling and threading methods suffer from the
fundamental limitation that the query protein sequence must be evolutionarily related
to some proteins with known tertiary structure [99]. For a query protein, if none of its
homologous sequences has an experimentally resolved structure, the only remaining
approach to predict its native structure is ab initio folding.
Ab initio folding attempts to find the native structure of a protein “from scratch”
(see Figure 12). The fundamental assumption in ab initio folding is the existence of a
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free energy function that assigns an energy value to each three-dimensional structure
the protein can in principle assume. The native structure is assumed to be the
one with the lowest energy. Although there are notable exceptions, this assumption
holds true for the vast majority of the protein native structures. Thus, there are
two main ingredients in ab initio folding: The design of a reliable energy function,
and the development of an efficient approach to the search the space of all possible
conformations for the one with the lowest energy. In this work, we focus on the first
problem, namely, finding an energy function which allows for efficient and accurate
determination of the native structure of proteins in an ab initio folding approach.
Figure 12: Illustration of Ab initio Folding
The energy functions used in ab initio folding are physics-based: for a given three
dimensional configuration of a protein, one first calculates various terms contributing
to the total energy such as electrostatic energy, covalent bonding energy, Van der
Waals energy, etc., and then adds these terms to obtain the total energy. While
these terms are based on physics, their functional forms are sometimes approximate,
and the coefficients that appear are obtained by various fitting procedures. In this
work, we represent the total energy of a configuration as a linear combination of these
physics-based energy terms, and optimize the coefficients.
For a given protein, we represent the total energy of a given, candidate three-
dimensional structure (conformation) s as f(s) = wTx, where x ∈ Rn represents the
collection of the energy terms for the conformation s, and w ∈ Rn is the weight coef-
ficients. The fitness of a given energy function can be visually inspected by plotting
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the total energy versus the structural dissimilarity to the native structure. For a given
protein with known native structure, one generates many possible conformations, and
obtains the total energy and dissimilarity from the native structure for each. There
are various notions of structural similarity used in the literature, such as the root
mean squared distances (RMSD) [62] between the building blocks (e.g., atoms) of the
protein as represented in two candidate structures aligned in three-dimensional space.
Figure 13: Energy versus Structural Dissimilarity Plot
Figure 13 shows such a plot for a desirable energy function. Each black dot
represents a non-native conformation. As can be seen, the energy value is higher for
conformations that have large dissimilarities from the native structure, with a roughly
monotonic trend. This trend should be reproduced by any ab initio folding procedure
,which starts with some random conformation and searches the space of all possible
conformations for the one with the lowest energy. Due to the monotonic trend,
reducing the energy corresponds to getting closer to the native structure during ab
initio folding procedure. If one can construct an energy function that has energy vs.
dissimilarity plots like that of Fig. 13, one can hope to reproduce a similar trend for
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proteins with unknown structure. As described below, we investigate the optimization
problem by suitable training and test sets of proteins and cross-validation.
Let xj be the vector of energy terms for the j-th conformation sj of a protein, rj
be the structural dissimilarity between sj and the native structure s0 , and Ej = w
Txj
be the energy of sj. Treating the weight vector w as the unknown, the task of learning
an ab initio protein folding energy function becomes a weight optimization problem.
Much of the literature on this problem is based on maximizing the correlation (or
related quantities) between the total energy and the dissimilarity. In this paper, we
propose a ranking-based approach to this problem. Namely, given m conformations
for each of a set of proteins, we propose to search for the weight vector w such that
for each protein, a meaningful subset of the constraints below are satisfied.
• Total energy of the native structure is the minimum, that is, E0 < Ej for all
j = 1, · · · ,m.
• Energy of random conformations with smaller structural dissimilarity are smaller
than those with larger dissimilarity, that is, if rj < ri, then Ej < Ei.
This chapter is organized as follows. We begin in Section 2 by converting the
weight optimization problem into a learning-to-rank task and then describe Rank-
ingSVM, a ranking-via-classification method that we utilize. Due to physicality con-
straints, we restrict the problem to non-negative weights. Two efficient algorithms to
solve the constrained RankingSVM problem are described in Section 3. In Section 4,
we analyze and discuss the experiment results.
4.2 Weight Learning By Ranking
The problem of learning protein energy function can be reduced into a learning-to-
rank problem if we consider the ordering derived from the structure dissimilarity as the
true ordering over the protein conformations, and the ordering derived from the energy
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function as the predicted ordering. The corresponding learning-to-rank problem seeks
to find a linear ranking function f(s) = wTx that optimally approximates the true
ordering of the protein conformations. In our study, for any query protein, we expect
the predicted ordering to satisfy the following requirements as many as possible:
i) Rank the native structure above other conformations
ii) Rank conformations with lower dissimilarities above those with higher dissimi-
larities
In this section, we review current machine learning approaches in learning-to-rank
tasks, and then describe RankingSVM, which is the basis of our proposed methods.
4.2.1 Learning-to-Rank Methods
The simplest class of learning-to-rank methods is the pointwise approach. It can also
be viewed as the ranking-via-regression approach. The most straightforward pointwise
objective function is the MSE (mean squared error) between the rank/score of an
object (e.g. a document, a protein conformation) in the true ordering and that in
the predicted ordering, e.g. RankProp [21]. Another option would be to use criterion
such as DCG (discounted cumulated gains) in the regression [30]. More sophisticated
methods include: framework of ordinal regression, e.g. PRank [31], etc.
Because it is generally easier to obtain/model the preference over object pairs
than the absolute rank order of objects, pairwise approach, also called as ranking-
via-classification approach, was proposed. Typical methods include: RankingSVM,
RankBoost, RankNet, etc. RankingSVM [50] seeks to maximize the Kendall τ statis-
tics [64], which can be approximated by minimizing the number of mis-ordered object
pairs in the predicted ordering. Rankboost [35] aims to minimize the weighted num-
ber of object pairs that are mis-ordered by the final ranking function. RankNet [17]
is a probabilistic model for learning the pairwise preference.
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Recently, listwise approach was proposed to directly tackle the ranking problem.
In this class of methods, ranked list of objects are treated as instances in learning
and the final ranking function is learned through the minimization of a listwise loss
function. ListNet [20], SoftRank [105], SVM-MAP [118] are examples of methods in
this category.
4.2.2 Ranking Via Support Vector Machines
Pointwise and pairwise approaches have the advantage that the existing theories and
algorithms on regression and classification can be readily applied into the learning
task. Moreover, pairwise approaches generally outperform the pointwise approaches
and have been successfully applied to Information Retrieval applications [59],[56], [17].
Therefore, we adopt the ranking-via-classification approach to solve our problem: we
first convert the data set by the difference space method [87], and then build a linear
classifier on the converted data set. That is, given a data set S = {(xi, ri)}mj=0, we
convert it into Sdiff = {zij = xi − xj, yij = Sign(ri − rj)}, where zij is the pairwise
difference vector, and yij is the sign of the rank difference of objects i, j. The optimal
linear decision function learned on Sdiff gives the optimal linear ranking function for
the original dataset S.
RankingSVM method seeks to find a ranking function f that approximately max-
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i=0 contains the energy data
of the qth protein, rank ordering o∗q is the true ordering of the protein conformations
derived from structure dissimilarity, and ôq is the approximated ordering determined
by the linear ranking function f(·).
Kendall’s τ statistic [64] for two finite orderings o∗q, ôq is defined as
τ(o∗q, ôq) =
concordant #− discordant #
concordant # + discordant #
,
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where an object pair si 6= sj is called discordant if the orderings o∗q and ôq do not
agree in how they order si and sj, and called concordant otherwise. In our study,
discordant pairs are pairs of protein conformations si, sj such that the learned ranking
function f(·) ranks si above sj, but the input preference (rj < ri) indicates sj should
have smaller energy than si; or vice versa.
For strict orderings onm instances, we have m(m−1)
2
= concordant #+discordant #.
This will give too large a training set in our case, and we will work with a suitable
subset below. A linear ranking function f(xi) = w
Txi generates an ordering on the
instances such that si < sj iff f(si) < f(sj). Maximizing the expected Kendall’s
τ statistic of a linear ranking function on the data set S = {(xi, ri)} is equivalent
to maximizing the pairwise agreement (concordant #). This optimization problem
can be formulated as a search for the weight vector w that maximizes the number
of inequalities of form Sign(ri − rj)wT(xi − xj) ≥ 1 that hold true. It can be ap-
proximately solved by learning the SVM classifier [109] on the transformed data set,
Sdiff = {zij = xi−xj, yij = Sign(ri− rj)}, where zij is the pairwise difference vector,







T zij ≥ 1− ξij, ξij > 0,∀i, j
(33)
4.3 Non-Negativity Constrained Weight Learning
The energy terms used in our optimization represent “costs”, in the sense that the
natural physical tendency of the protein is to decrease each one of these values. Each
energy term, taken separately, represents a uniquely defined physical tendency. For
the case of electrostatic interactions, two positive charges move away from each other
in order to lower their interaction energy. Reversing the sign of this interaction energy
would turn the repulsive force to an attractive one, hence resulting in an unphysical
interaction. If we sacrifice the physicality of the energy function by picking negative
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weights for some terms, it may be possible to obtain a better ranking on the collected
set of conformations. Unfortunately, experience shows that such unphysical energy
functions, while performing well on the chosen set of existing proteins, perform poorly
when predicting new physical structures. This is partly because it is impossible to
sample the whole set of possible conformations for a given protein, and the methods
used to generate the conformations in the training set start from special, compact
conformations that already satisfy various physicality properties. Dropping the posi-
tivity constraints could improve the ranking for these special conformations, but there
will be very large, unsampled subsets of the set of possible conformations where the
negative coefficients would result in incorrect foldings/orderings. Thus, one enforces
a positivity constraint on the weights in order to avoid overfitting to the (small) set
of sampled conformations.
We next describe two approaches to non-negative support vector machines (NNSVM).
4.3.1 Non-Negative L2-norm SVM
In this section, we propose a non-negative version of SVM by using an L2 norm
approach, and solve it through the exponential gradient (EG) algorithm [65].
Due to the characteristics of our problem, we formulate the optimization in primal









1Tl (1l −DAw)+ (34)
where (u)+ = max(u, 0) sets the negative components of the vector u to zero, A
denotes the data matrix with rows given by the zijs, D = diag(y1, · · · , yl) is the label
matrix, 1l = [111 . . . 1]
T is an l-dimensional vector of 1s, and l is the total number of
data points (i.e. total number of pairwise difference vectors in our study).
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The objective function in Eqn. (34) is non-differentiable, hence typical optimiza-
tion methods cannot be directly applied to this problem. To address this issue, we
use the L2-norm of the hinge loss variables in the objective function. This type of
SVM has gained popularity in large scale classification because the resulting objective
function J(w) is a piecewise quadratic and strongly convex function, and efficient al-
gorithms such as coordinate descent [25] can be applied. The Non-Negative L2-norm








|| (1l −DAw)+ ||2 (35)
We use the exponential gradient (EG) algorithm [65] to solve this NNL2SVM
problem because its optimization is naturally constrained to the non-negative space
Rn+. The algorithm is summarized in Table 16.
Table 16: EG Algorithm for NNL2SVM Problem
Initialize w0 = 1
n
1n so that || w0 ||1= 1
For t = 0, 1, 2, . . .
Compute 5J(wt) = νwt − 1
l
ATD(1l −DAw)+
For all j = 1, · · · , n





where the learning rate η = 1/R with R = maxij(maxk zij,k −mink zij,k), where zij,k
denotes the kth component of the feature vector zij = xi − xj. R is the largest value
over the sample set of the maximum difference maxk zij,k − mink zij,k between the
components of a feature vector zij.
The standard normalization sets || wt+1 ||1= 1. We also investigate another
normalization method that enforces || wt+1 ||1≤|| wt ||1 by keeping wt+1 unchanged if
|| wt+1 ||1 is less than || wt ||1, and setting its norm to || wt ||1 otherwise.
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4.3.2 Non-Negative L1-norm SVM
Another approach to the NNSVM problem is to add non-negativity constraints to the
L1-SVM formulation [13] and extend the existing L1SVM algorithm [37],[74] to solve
the resulting NNL1SVM problem. The optimization problem is,




DAw ≥ 1l − ξ
w, ξ ≥ 0
(36)
We solve this problem using an approach described in [74]. Proposition 1 in [74]
states that for any ε ∈ (0, ε̄] for some ε̄ > 0, the optimal solution of the exterior penalty
problem gives an exact solution to the original, primal problem. The corresponding
exterior penalty problem can be derived by assigning quadratic penalty terms to the
constraints of the dual problem. The exterior penalty problem of Eqn. (36) minimize
the following objective function,
J(µ) = −ε1Tl µ+ 12(|| (A
TDµ− 1n)+ ||2 + || (µ− π1l)+ ||2 + || (−µ)+ ||2) . (37)
Problem 37 is an unconstrained optimization problem. We solve it using the
generalized Newton method described in Table 17.
Table 17: Newton Method for NNL1SVM Problem
Initiate t = 0 and µ1 = 1l
Repeat
t = t+ 1
µt+1 = µt − ζt(δIl + ∂2J(µt))−15 J(µt)
ζt is the largest number in {1, 12 ,
1
4
, · · · , }
such that J(µt)− J(µt + ζtdt) ≥ − ζt
4
5 J(µt)dt
where dt = −(δIl + ∂2J(µt))−15 J(µt)





Following the definition of generalized Hessian in [74], the gradient and hessian
for Eqn. 37 are given as,
5J(µ) = −ε1l +DA(ATDµ− 1n)+ + (µ− π1l)+ − (−µ)+
∂2J(µ) = DAdiag{(ATDµ− 1n)∗}ATD + diag{(µ− π1l)∗ + (−µ)∗}
where u∗ = Sign(u+), with Sign being applied element-wise on the vector.
Notice that at each Newton iteration, we need to invert the matrix Q = δIl +
∂2J(µ). This is computationally expensive when the total number of data points l
is large (l > 1000). We address this issue by using the Sherman-Morrison-Woodbury
formula [39] and reduce the time complexity from O(l3) to O(ln2) + O(n3). The
inversion of the hessian matrix Q can be computed as follows,
Q = F +H ∗HT
Q−1 = F−1 − F−1H(Il +HTF−1H)−1HTF−1
where diagonal matrix F = diag(ρ) with ρ = δ1l + (µ− ν1l)∗+ (−µ)∗ and ρ > 0, and
matrix H = DAE with E = (diag(ATDµ− 1n)∗)
1
2 .
4.4 Results and Discussion
4.4.1 Data Set Description
The dataset used in this study consists of the values of various energy terms for a
non-redundant set of 171 proteins that fall into the ab initio folding class. This set
is representative of the “hard target” protein sequences in the Protein Data Bank
with up to 200 residues, meaning that current homology search tools fail to identify
proteins with an evolutionary relationship with proteins in this class.
For each protein, a large set of non-native random conformations (around 51, 000
to 63, 000 per protein) are generated in the manner described in [121]. The energy
terms for the native structure and each one of the generated conformations are col-
lected. The energy terms are obtained from the CABS (Cα-Cβ-Side chain) force
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field [121], which is used in the protein structure prediction tool TASSER [123]. We
include 20 different energy terms from this force field, briefly summarized in Table 18.
Table 18: Energy Terms used in TASSER
E∗,1 pairwise interaction of Cα-SC (side chain)
E∗,2 pairwise interaction for non-parallel Cα-Cα
E∗,3 excluded volume of SC-SC
E∗,4 pairwise interaction of SC-SC
E∗,5 quarsi3 for SC-SC
E∗,6 enhance good piece
E∗,7 -1/r for parallel contact of Cα-Cα
E∗,8 hydrogen bond interactions on the alpha helix
E∗,9 hydrogen bond interactions on the beta sheet
E∗,10 bury potential for SG (side group)
E∗,11 bias2,3 :
v(i)− v(i+ 4) anti/parallel
c(i)− c(i+ 2) anit/paralel
E∗,12 crumpling
E∗,13 bias4 to predicted secondary structure
E∗,14 bias1 to possible secondary structure
E∗,15 correlation of E13 of Cα
E∗,16 correlation of E14
E∗,17 correlation of E15
E∗,18 environment potential
E∗,19 deviation from predicted contact order
E∗,20 deviation from predicted contact number
The structural similarity of conformations is measured by the TM-score [122],
which is intended as a more accurate similarity measure than the commonly used
root-mean-squared distance (RMSD) [62] between the the conformations. The values
of the TM-score range between 0 and 1, with 1 corresponding to a perfect match
between two conformations. We are seeking a large correlation between structural




In an earlier optimization study [121], the authors proposed to use an objective func-
tion (G1 ∗ G3) related to the correlation corr(r(q), E(q)) between the structural
dissimilarity and the total energy of the generated conformations. Namely, they used











where Zn(E(q)) = (Ē(q) − E0(q))/(
√
Ē2(q)− (Ē(q))2) is Z-score of the mean of
the total energy.
Using the CERN MINUIT package [58] to optimize the weights, they achieved sig-
nificant results in CASP [123],[125]. Their study employed proteins from all homology
modeling, threading, and ab initio prediction classes.
4.4.3 Experiment Design
The number of all pairwise difference vectors zij = xi−xj is quadratic in the number
of data points (conformations). In addition to this computational issue, it is not
realistic to expect the energy function to rank all conformations according to their
dissimilarity from the native structure. Thus, instead of working with all possible
pairs of conformations, we design a sampling approach as follows:
• For the first class, we sample 100 non-native conformations and include their
comparisons with the native structure, i.e., C1 = {zi0 = xi−x0 | yi0 = sign(ri−
r0) = 1}. We sort the set of conformations by dissimilarities to the native
structure and perform a uniform sampling.
• For the second class, we generate pairs of comparisons between non-native struc-
tures. If two conformations have close values of dissimilarity from the native
structure, it may not be reasonable to require the energy function to rank them
74
according to the dissimilarity. After all, conformations with very different struc-
tures can have close values of dissimilarity to the native structure, and in such
a case it is not easy to clearly identify which one is “better”. For this rea-
son, we restrict the second class to pairs whose dissimilarities from the native
structure are sufficiently different. In particular, we first partition the set of
non-native conformations into 6 subsets, S(0,0.1), S[0.1,0.2), · · · , S[0.4,0.5), S[0.5,0.6],
where S(0,0.1) contains conformations with dissimilarity from the native struc-
ture in the range (0, 0.1), S[0.1,0.2) contains conformations with dissimilarity in
the range[0.1, 0.2), etc. We then uniformly sample 25 conformations {s(j)i }25i=1
from each subset S[aj ,bj), and sort them according to dissimilarity. The com-





























25 ). For each of these comparisons,
the class yij = sign(ri−rj) = −1. By picking the pairs in this way, we make sure
that the minimum difference between the dissimilarities of any pair included is
at least 0.1.
One may ask whether the class labels ±1 matter; by reversing the order of the
conformations in any given pair, the corresponding data point for the SVM changes
its class. How should one pick which order to use? It turns out that this order/class
assignment is irrelevant, since for the ranking SVM which has no offset, one ends up
with exactly the same optimization problem after such a reversal.
By the sampling method described above, we generate 100 data points in each
class, for each protein. This gives a total of 34, 200 data points of dimension 20.
4.4.4 Performance Measure
In order to compare alternative methods of energy function optimization, we need ap-
propriate criteria. The ultimate test is, of course, folding; given two energy functions,
one runs a folding algorithm with each in order to see which one performs better for
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a test set of proteins. We leave this ultimate test to our future work, and describe
criteria that are suggestive of the expected performance of energy functions/weights.
(a) 1tluA (b) 1ayoA (c) 1vk5A (d) 1kafA (e) 1dwnA
(f) 1pp7U (g) 1xzpB (h) 1b79A (i) 1azzC (j) 1d7mA
Figure 14: Representative Energy versus Structural Similarity (1-(TM-score)) Plots
As we have suggested in the introduction, the performance of a protein energy
function can be evaluated descriptively through plots of the total energy versus struc-
tural dissimilarity for each protein of the test set in a given cross-validation fold. The
plots can illustrate possible ab initio folding paths of a protein, starting from a ran-
dom conformation with high structural dissimilarity, moving to the native structure
or near-native conformations by reducing the value of the energy function. In order
to give some visual indication of the quality of the energy function resulting from our
optimization, we display in Figure 14 ten representative test-set plots of total energy
versus dissimilarity (1-TM score) for weights obtained using RankingSVMNNL1 . Each
dot represents a decoy structure, and the thick red point (roughly in the bottommost,
leftmost end of the plot) represents the native structure.
Desirable results are shown in (a) and (d) for proteins 1tluA and 1kafA, respec-
tively. Due to the consistent, monotonic trend, reducing the total energy by changing
the conformation corresponds to increasing the similarity to the native structure.
Thus, one expects the learned energy function to result in rapid ab inito folding from
a random conformation. Plots (b) 1ayoA and (g) 1xzpB show good, monotonic re-
gions together with highly undesirable, deep local minima where the folding procedure
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may get stuck. Plots (c) 1vk5kA, (f) 1abc and (h) 1b79A show good behavior near
the native structure, leading an energy minimization procedure towards the native
structure, while having trouble for random structures that are highly dissimilar to the
native structure. (e) 1dwnA and (j) 1d7mA represent highly undesirable cases, where
there is no observable relation and negative correlation between the dissimilarity and
energy, respectively.
While such plots are descriptive of the general characteristics of an energy func-
tion, one would like to have a quantitative measure of performance. In the previous
approach used in TASSER [123], the objective function G1 ∗G3 we described above
was used as the performance measure. However, this is an ad hoc objective function
whose direct relationship with folding performance is not clear.
In the following, we use two criteria to evaluate the fitness of the learned energy
functions. The first one, Pearson’s correlation, measures the strength of the linear
relationship between the energy and the structural dissimilarity. We expect the re-
lationship between energy and dissimilarity to be nonlinear, with outliers, unequal
variances, and non-normality. Thus, while it is a useful first test of an overall linear
dependence, we do not expect Pearson’s correlation to give an accurate prediction of
the folding performance that will be achieved by using a given an energy function.
The second approach we use for evaluating energy functions is more flexible, and
possibly more useful: we compare the rankings of the conformations provided by the
total energy and the dissimilarity from the native structure. Since ab-initio folding
approaches work by modifying conformations to reduce their total energy, we can
expect to obtain accurate folds when reducing the total energy corresponds to re-
ducing the dissimilarity to the native structure, i.e., when the relative order of two
conformations given by the energy and the dissimilarity agree. This approach does
not give a particular importance to linear relations; all that matters is the degree to
which there is a monotonic relation between the energy and the dissimilarity to the
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native structure.
One of the most popular statistics used to compare two rankings of a set is
Kendall’s τ statistic [64]. This defines the distance between two rankings of a set
as the number of pairs that have the opposite ordering in the two rankings. In our
problem, the two rankings of the collected conformations are given by the total en-
ergy and the dissimilarity from the native structure. We approximate the expected
value of Kendall’s τ statistic for the these two ranking functions through the sampled
pairwise agreement between the ranks they assign.
4.4.5 Results Analysis
We evaluate our RankingSVM approach to learning protein energy functions through
10-fold cross validation. We randomly partition the 171 proteins in our data set into
10 folds. For each fold i, we learn an energy function from the energy data of the other
9 folds, and evaluate the learned energy function on fold i. As described above, we use
two normalization schemes in the optimization of the NNL2SVM method. We denote
ranking via NNL2SVM with the normalization rule || wt ||1= 1 as NNL2SVMn1,
and ranking via NNL2SVM with the normalization rule || wt+1 ||1≤|| wt ||1 as
NNL2SVMn2. Ranking via the NNL1SVM method is denoted as NNL1SVM.
The baseline method in our experiments consists of optimizing the objective func-
tion G1 ∗G3 using the MINUIT package. Since G1 ∗G3 is not a convex function, the
solution depends heavily on the initial weights. TASSER protein structure predic-
tion program sets the initial weights based on domain knowledge on the importance
of the energy terms, as well as the proteins in the training set. This initialization
procedure will be too expensive for our random 10-fold cross validation. Therefore,
in our experiments, we tried 1000 sets of initial weights randomly generated from the
set {0, 1}20, and then selected the ones with the smallest G1 ∗ G3 value (we remove
the results that having Zn(w) ≈ −1).
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4.4.5.1 Parameters Tuning
We employ the grid search procedure for choosing the right parameter setting for
NNL2SVM and NNL1SVM methods. Note that for NNL2SVM method, we need to
tune the parameter ν > 0, and for NNL1SVM method, the tuning parameter are
π > 0 and δ > 0. The candidate values of the parameters used for the experiments
were
• ν, π ∈ {10−3, 10−2, 10−1, 1, 101, 102, 103}
• δ ∈ {10−3, 10−2, 10−1, 1, 101, 102, 103}
For each parameter setting, we perform a 10-fold cross-validation and obtain
the average score over the 10 folds, the averaged training performance over cross-
validation. The parameter setting with the best score (ties are broken randomly) is
chosen for the final comparison.
4.4.5.2 NNL2SVM versus NNL1SVM
We first analyze the trend of the sampled pairwise agreement and the sparsity of
the weight vector during the algorithm optimization of the proposed NNSVMs. For
NNL2SVM, we observe the testing accuracy and the sparsity at iterations {1, 2, 5,
10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 10000, 20000, 50000, 100000} during the
exponential gradient (EG) optimization. For NNL1SVM, we observe at iterations {1,
· · · , 20, 25, 30, 35, 40, · · · , 100} during the Newton optimization.
As shown in Figure 15(a), NNL2SVMn2 (shown as red squares) outperforms
NNL2SVMn1 (blue triangles). While the latter converges earlier, it does so at the
cost of lower accuracy. NNL1SVM (Figure 15(b)) converges only after 20 Newton
iterations. Unlike the NNL2SVM methods, its performance during optimization is
irregular. But it still indicates an overall trend of increasing accuracy.
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(a) NNL2SVM Accuracy (b) NNL1SVM Accuracy
(c) NNL2SVM Sparsity (d) NNL1SVM Sparsity
Figure 15: NNSVM Optimization Methods Comparison
In Figure 15(c), (d), we see that NNL1SVM achieve low sparsity after only a few
Newton iterations, while NNL2SVM methods gradually obtain sparse solutions after
about 50000 EG iterations. NNL2SVMn1 generally obtains sparser solutions than
those of NNL2SVMn2 , but at the cost of accuracy. The nonzero energy terms chosen
are as follows. For NNL2SVMn1 , the consensus is terms 2, 7, 9, 12, 18, 19, 20. The
results from NNL2SVMn2 agree, with addition of energy term 16. For NNL1SVM,
the preferred terms are 2, 9, 18, 20. The biochemical meaning of these combinations
are under investigation.
4.4.5.3 RankingSVM versus TASSERMINUIT
We then measures the performance of the energy function learned by each method
using both Kendall τ statistics (approximated by sampled pairwise agreement) and
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Pearson’s correlation. Figure 16(a) lists the sampled pairwise agreement, measured
by testing accuracy on the labeled pairwise difference data over the 10-fold cross
validation. Figure 16(b) list the average correlation coefficients between the rmsd
value and the energy, which are computed using the learned energy function during
each cross-validation.
(a) Pairwise Agreement (b) Correlation
Figure 16: Error Plot of the Performance of the Learned Energy Functions
Comparing to the energy function learned by baseline method, the energy func-
tions learned using RankingSVM methods generally have better performance in both
sampled pairwise agreement and correlation. The energy functions learned using
RankingSVMNNL2 method can achieve around 8.7% increase in the sampled pairwise
agreement and around 33.7% increase on the correlation values on average, while
those output by RankingSVMNNL1 method have around 9.7% and 28.3% increase on
those values, respectively. In addtion, the average computation time of a 10-fold
cross validation for RankingSVMNNL1 is about 7 seconds, which is much more effi-
cient comparing to RankingSVMNNL2 methods (around 20 minutes) and the baseline
method (around 2 minutes). Overall, we can conclude that RankingSVMNNL1 method
outperforms the other methods in terms of learning performance as well as efficiency.
4.4.6 Discussion
A critical open problem in ab initio protein folding is protein energy function de-
sign. We address this problem as a weight optimization problem, and demonstrate a
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machine learning approach using the ranking-via-classification paradigm. Due to the
nature of the commonly used data generation procedures, the sampling of the non-
native conformations used in the training set is restricted to a small subspace of the
space of all possible conformations consisting of compact configurations. In order to
avoid a tendency to overfit to this subspace and preserve the physicality of the energy
function, we restrict the problem to non-negativity weights. We develop two effi-
cient algorithms, NNL2SVM and NNL1SVM, to solve the constrained RankingSVM
problem. Comparing with state-of-the-art approach that based on maximizing the
correlation between the total energy and the structural dissimilarity, our learning-to-
rank approach was able to learn energy functions that maintain the correct ordering
of the conformations more often, and give higher correlations with the dissimilarity
from the native structure. In addition, NNL1SVM, the method with the highest




Bioinformatics is a growing application area of machine learning. Many of the com-
putational biology problems can be reduced into supervised learning problems. In
this thesis, we extend support vector machine optimization, which has been show
superior classification performance theoretically and empirically, to develop efficient
algorithms on the reduced machine learning problems and provide useful tool to assist
the biologists. To examplify our approach, we solve problems from three classes of
important bioinformatic application including cancer diagnosis, biomarker discovery
and protein energy function learning.
We investigate predictiveness of metabolic profiles generated by Direct Analysis
in Real Time (DART) from patient sera. We reduce the task of classifying DART
MS profiles into a functional classification problem and solve it using functional SVM
method. The assay distinguished between the cancer and control groups with 98.9%
accuracy (100% sensitivity; 98-100% specificity) under leave-one-out cross-validation
evaluation. We view this as a successful step towards the development of an accurate
new approach to the diagnosis of ovarian and other cancers.
We explore convex relaxations of L0-norm SVM for developing more aggressive
feature selection methods to assist high throughput biomarker discovery. We study
mixed-integer support vector machine and solve it with mixed-integer nonlinear pro-
gramming technique. Empirical study shows encouraging result, simultaneously im-
proved feature selection and prediction performance on small/medium feature size
data sets. We also propose an practical solution to solve the fractional-norm SVM
problem with difference of convex programming technique. Empirical study support
83
the effectiveness of the fractional-norm SVM over other commonly-used sparse SVM
methods. We believe our approach is a promising direction for feature selection in
high-dimensional low-sample size data sets
We address the open problem of learning energy function for ab initio protein fold-
ing as a weight optimization problem and demonstrate a machine learning approach,
learning to rank, to solve this problem. To maintain the physicality of the results,
we impose non-negativity constraints on the weights and develop two non-negative
support vector machine methods (NNL2SVM and NNL1SVM) for the constrained
RankingSVM optimization. Comparing with the state-of-the-art approach, our meth-
ods result in energy functions that maintain the correct ordering of the conformations
more often, and give higher correlations with the dissimilarity from the native struc-
ture. Furthermore, the ability to learn SVMs with non-negative weights is a more
general capability which we anticipate have applications beyond protein folding.
5.1 Future Work
Incorporate Domain Knowledge into Biomarker Discovery
Feature selection methods that utilize cancer data (e.g. gene expression data,
or metabolite intensity data) alone may be insufficient to produce biologically com-
pelling biomarker candidates. The main reason is that these data sets only monitor
one level of biological regulations, of which there are many levels in cancer patho-
genesis. Furthermore, many of these low sample size high dimensional data sets are
linearly separable between different patient groups, hence the classification problem
on these datasets is too simple, admitting too many possible solutions in such a high-
dimensional space for us to be able to pinpoint critical features. Changes on the
training data subsampling often results in completely different feature selection re-
sults. One possible solution to boost the biological significance and stability of feature
selection results would be incorporating domain knowledge, which is generally used
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in the biological validation process, into the feature selection process.
We have explored on incorporating gene ontology information [5, 29] into the
statistical microarray analysis [42]. The method can be described as in Table 19. We
conduct experiments on a 43×12, 558 ovarian cancer microarray data generated from
Affymetrix U95Av2 chips (containing 10 are benign cancer patients; 9 are malignant
cancer patients with no chemotherapy treatment; 24 are malignant cancer patients
with chemotherapy treatment). The results showed that this method is capable of
recovering biomarkers such as TUMOR PROTEIN 53 (TP53), a verified biomarker
for ovarian cancer, whose expression values are not significantly different between
patient groups, but instead may be mutated or regulated at the post-translational
level through ontological links from geno ontology.
Table 19: Incorporating Gene Ontology into Biomarker Discovery
Divide genes into function groups according to gene annotations
Compute the discriminative capability of each function group
Obtain the gene expression submatrix of the jth function group
Compute SVM accuracy on the gene expression submatrix
Compute SVM accuracy during feature selection process on the data set
Score the function group with LOOCV full and best LOOCV
Rank genes according to the scores of the functional group it belongs to
Normalize on the gene score (Optional)
Still, further investigations are required in order to apply this idea to biomarker
discovery in general. For example for metabolites panel selection, many metabolite
might not be annotated since metabolite cancer biomarker is not as extensive studied
as large polymers cancer biomarkers (such as genes). In addition, the annotation on
the mass spectrum is not as straightforward as gene annotation and still requires a
lots of input from domain experts, for example, mapping m/z values into mebabolite
mass for metabolite identification. We would also like to explore other ontological
information (such as KEEG [63]) to see their effect in boosting the biological signifi-
cance and stability of feature selection results.
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Energy Function Learning
While our proposed non-negative RankingSVM approach is a promising direc-
tion for learning energy function for ab initio protein folding, further improvements
might be needed to assist the biological validation task: folding proteins. As the
rankingSVM problem is contrained with non-negativity weights, many of the weight
elements are threshold to zero during the optimization. As the data set only consists
of a small subset of all the possible conformations of a given protein, energy function
with just a few energy terms (i.e., sparse weight vector) might have a tendency to
overfit to this subspace. It is possible that the energy function performs well on the
chosen set of existing proteins, while perform poorly when predicting new physical
structures. Thus, denser solution of the weight vector is preferred in order to avoid
overfitting to the sampled conformations.
We can address this issue by constraining the rankingSVM problem with a more
general boundary condition w > w0, where the boundary weight values w0 6= 0 can be
determined using domain knowledge on the energy terms. Given the updated opti-
mization formulation described in Table 20 and the boundary vector w0, we can easily
modify our optimization algorithms (see Table 16,17) to solve the revised rankingSVM
problems with general boundary conditions.





|| (1n −DAw)+ ||2
s.t. w ≥ w0
min 1Tdw + c1
T
n (1n −DAw)+
s.t. w ≥ w0
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